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INTRODUCTION: TI lE BURDEN OF CARDIAC DlSI:ASE IN ESlm.
End-stage renal disease seems to be inextricably tied to cardiac diseuse. I'Iydc Shields, the
first patient with end-stage renal disease sustained on dialysis over u I l lll ~ period, died Ill'
myocardial infarction ill 1970. at age 50, ancr I I years lll' hclllodialysis IIK'Wpy t I). t\pprtlXillmld~
half of all dcnths seen in end-stage renal disease (l~SRnl pruicrusnrc ouributcd ro e:lI\lio\'aselll:lr
disease: this figure is rcmarkuhly slmllar throughour the workl t:!..~ Aj . fl.7 .x.(). 1U) , ( ·ardil1\'asclilar
disease is freq uently already present ill patients rcuchlng end-stage rc"al diseuse and 1II1dollhll'dly
contributes heavily 10 the excessivecurdlcvnscular morbidity nndmortulitySel.'11 in puticms I ' ll renal
replacement therapy (2,3.4,6). For example. in Ihe United Stutes Rcual Data System (I :SHIl S,
SpecialStudy ofC nsc Mix Severity Ilf3.31J9 patients starting chronic hcmodlulyxls. curonuryartery
diseuse wus already present in 40,1l% of patients: for cardiac failure. the corrcspcuuliug ligure wns
4 J,I% (2). In patients beginning renal replacement therapy in ('a nada ill 19'J2. 21,9%,lunlu hislllr)'
uf uugiua pectoris, 17.5% myocardial iufurctiou. 29,0% pulnunurrycdcrna. HJ')I"ccrcbn.vnscntnr
nccldcnt.while \4.8% had peripheral vasculardiseuse(4). Pre-clinical cnrdiovnseulnr:lhI H 1I"l nil Ji1ic.~
nrc even commoner. Non-invasive studies, princtpntly using cchocardiography. II.I\'(' etlllSiSlellll)'
shown that up to IlO% of patients starting renal replacement therapy have structural or Iunctlonnl
nbnormaihics ofthc Icll velltric1e(1 1.l 2.I3.14 ) as wus scell in thc currcnt suuiy t lSj
There is a high incidence of de 1l0 VO cardiovnsculur diseuse in ESIU) paticrus. A recent
Japanese study followed \609 dialysis patients prospectively fill' 3 years. U.~irlg the ugc-mntchcd
general population as reference category, the relative risk of'cerebral infarction was 2.U.eerchml
hemorrhage 10,7, subarachnoid hemorrhage 4.0 and acute myocardial infarction 2.1 (\(1), III the
Cunndinn Ilemod ialysis Morbidity Study. the unnuul incidence or myocurdiul infarction and
congestiveheart failure were buh ]0% peryear (17).
Ihc high burden Ill' disease. :!JIlJ theneed for high quality clinical studies were strongly
highlighted ill II recen t consensus document from the United States Nruional Institute of IIcnhh
(IK ).
Between 19K2 and 1991. a cohort or 433 inception dialysis patients was follo wed
prospectively for an uvcragc 01'41 months. All these patients survived for greater than 6 months on
ESHDtherapy. and had iUl ccbocnrdiogmmwithin II year of starting therapy. The primary purpose
of this study were tn delineate the prevalence. natural history prognosis and risk factors to r the
(t i tlcrclltllllltli fi.·slat ion.~ " I'cardiac diseuse in I ~S RD. The ultimate nim of this study was to idcnlily
<I n.:as arucnublc IIIintervention. preferably b)' means ofrundomiscd controllc-I trials.
OVERVIEWOF METlloDS
PATIENTS. This prospective study was started in the Royal Yictoriu !lospil"l. Montreal.l.lud1l"~·
in 1982. in the llcnlrh Sciences Centre St. John's, Newfoundland in 19N4. and in the l ; r,ll'~'
Hospital. St. John's. Newfoundland in 19&5. Pntiemswere c1igihk· for entry tothe Shldy i l'( a l lh~'Y
hnd survived for 6 monthsand jbj they had atcchuically satisH.ctlll"Ycchocurdiogmm within a yc.n-
of initiating rcnat rcplnccrncrutherapy. Paticntrccminucntat all J centers linishl'd inJune IlJlJI.
0['5 18 patients who survived ut kas t6 months from the sturt ofcnd-stngc renal diseuse
therapy a cohort of 433 (83.6% of tl-csc screened)entered the study. N5 patients were e.\t:llIlkl\
from the study lor thc following reasons failure to ontain u technically satb l;le tu r~
cchocurdiogmm withina year of starting therapy . 71 patients: started therapy clscwhcre, 71'1Il iellts
: patients' charts mislaid - 5 patients: 2 patientsdid not wish In particlputein the study.
Baselinecchocurdlogmphy was perfor med at II mean (stalldal'l dcviHtiull) intcrvntof .1.1
(3 .9) months from the time of firstdialy:>is. Themean (standard dcvinnorn durutionofnnal folluw-
up was 41.1 (25.7) months. Hemodialysis. peritoneal dialysis und rcnultransplantntion accounted
('11 average for 18.8, 12.8nnd 9.5 months respectively ofthe total follow-up.
T he clinical anddemographic chnracteristlcsufth c patientcohort. ut lhe timeuf stutly entry .
me shewn in Table 1. Overall. the age lind proportionof dinbctic patients were shuifur to oilier
Canadian end-siege renal disease programs (17). Compared 10 1Itypical program ill tile United
States there were more males (64% vs.52%) and fewer dinbctics (27% vs. J2'v,) (21,The study
group wasalmost entirely Caucasian.
DATA CClI.I.ECn oN . AI baseline, and at yearly interva ls Ihcl'C'.lficT. a clinical assessment WiL~
undertakenIII dl'll"l1 risk faclllr.> for and the pn:~"T'ICC of cardiovusculnr disease. Baseline :lIlti
Olll llllitllochlll:ilrtlillgmphy WiIS p....lun "'-"l.I using M-mooe mxJ 2odinl\:n.~icllla l uhrasooography. Lell
vcmricufurmas.~ index WlIS calculated using the Pen n convention (19). Le fi ventricular cavity
volume W,L~ l:a1culall"l.l by the formulaof Pomboct a!' (20) I.en ventricularmass and cavity volume
were indexed to hellJy surface urea. presented in g/m2 und ml/m.'. res pectively. where possible.
imaging W:IS curried nut when the patient had achieved "dry weight". the weight below which
hypotension or symp toms such , IS musclecrampsoccur.
IU':"'INITI(INS. The fallowing definitions were used.
t 'oron ary artery disease : history of myocardial infarction. coronary artery bypass SU'l:l'1')' or
p.·n:ul'lltl·tllL~ 1 r.IIL~l llminal angillpla.~ty.
Angin.1 p.ocillris: pl\."l·unJi:11cbcstpain. pn..'cipitulL'tIby exertion or stress, relieved by 1\."Sl. or nitrates.
bd'll.'luiclcart tlist....sc: ;J.nginaP."'Clori..or curonaryarterydiseuse,
( ':mliae Hlilun:: dyspneaplus 2 llfthe following - raised jugular venouspressure. bibasalurcrackles.
I'UIIl111nary \'C IlO US hypertension or interstitial edema on chest X-ray.
Peripheral vasculardiscase·: symptomsof. or surgery for peripheral vascular disease.
lIy srhylhmiu: atri n1or vcuuiculnrrhythmdisorder requiring therapy.
Arterialpulsepressure: systolicminus diustolic hloodpressure.
"'IC:Ulunerial pressure: diastolic blood pressure+ lf3(artcrial pulse pressure),
LV lli!:1Iation: cavit y volume > lXlml/ml (20) ,
(l i t
Concentric LV hypertrophy: hypertrophy with normal cavity volume (:!:!). lluctional shortcning
greatcrt hnn25%.
Ececntric k it ventricular hypertrophy: hypertrophy with I.V tlilutntiou, n~ICl il lllal ShllJ'lClling prc.ucr
than 25% (22).
Systolic dysfunction tractional shortening less than or cqualro :!5'Y" on Cd l\lCllnliography.
Abnormal leli ventricle: ally Ill' the following - l.V hypertrophy. I.V dilnuuion or systolic
dysfunction.
Cardiac mortality: death reco rded as "myocurdiul infarction". "sudden de:hh" or "other curdiac
causes".
ANALYSIS. Patient follo w-up started with the first dialysis treatment. The primary IHtlCOll1C
measure was death on dialysis therapy. Ovcrallmo rtnlityand death utter 2 years wereassessed. We
chose the latter end-point lor the following reasons: firstly. because a 11111': interval between
exposure 10 a risk factor nnd snhscqucntmortnlitymight be needed. and secondly. bccuuscwe k it it
likely that the independent haz..ards nssoclatcd with ditlcrent vurlnblcsmight nut rcnmiuconsnmt in
lime Frames as long as those seen in this study. For the analyses in this reporl. I'l:llk nts were
censored ruthe time orrcnultrunsplnntutionor at IilmJ follow-up. The survlvul analyses presented
hcre used the day of first dialysis as entry point. Using (, nnmths on dialysis as entry point led to
ulmost identical results. Cardiac mortality was a seeondnry end-point. C1inic:!1episodes of cardiac
li.illITe und ischemic heart disease following the initiation of ESRD therapy were analyzed
similarly.
Normally distributed continuous variables were comp arexl using t-tcsts. Categorical
variables were compared using ch i-squar ed ana lysis. Stepwise logistic regression analysis was used
'II assess theussociutkmsof'the differcm tell ventricular abnormalities present on first and follow-
up cchncardiogmphy. Stepwise multiple linear regression was used 10 assess the independent
nssocunions of continuous variables. such as idi ventricular mass index. cavity volume nnd
Irnctionnl shortening. Univariate survival analysis was carriedout using the product-limit method .
Thc indepe ndent power of different varlebtcs to predict death. ischemic heart disease and cnrdinc
li,illire Wll S assessed using Cox's regressionanalysis. The suitabilityof this model was assessed by
splil validation, in which dntnderived from a randomlygcnermcdsample of 2/3rds of nil patients
(lest .~H1 l1p l e ) were used 10 predict the survival of lhe remaining 113nl (validation sample). The
t 'ox's regrcssiun modcl accurately predicted the ncuml survivalof boththe test samj-Ic(suggesting
high 11degree(If goodnessof li t) and ihc validation sample(suggesting the ability of the model to
predict futuremortality.
Addhionnlly , OcC:IUSC variab les such as mean culclum lcvcl coul d vary direc tly us a function
of lime en dialysis and could lead to a spurious associationbetween calcium levels and mortnlity.
we examined thispossibility by testing these parameters as time-dependent variables given by the
fonnulu : [Xlooli '" [Xl.lulsurvivnlt imc]. where X is the level of thevariable being tested (23). Such
un adjustment procedure gives more weight In an nbnormul variable which has been present for a




JlRINCII'AI, OUTCOMESDURING TIlE STUDY (Tahle2 ).
'J1 1l~ ovcmllmcdiensurvival rOTthe patient cohort was 5(1 months.The 149dcatl ls observed
(luring thestudy period wereuuributcdto : myocardial infarction-Hl.I'x.,sudde n dcath-2 5.5%. othe r
card iac C:lusc s· II.4%,. other vascular t1isc1:Isc-lU.7%, inlcclioll·[4.0%. treatment wilhdrLIwnl-12.1%
and other ctluSl'S· IS.4%. The other majo r clinical andcchocardiogmphic outcomes arc shown in
Table 2. which shuwsa verylarge burden of'cardinc disease. b nhclinicaland cc homrdiographic.
CU N ICAL AN D Eel IOCARDIO GRAPI-fIC ABNO RMALITIESAT BASELINE:
PI{EVI\L ENCEAND ['ROG NOS!S (Tables 1 to 3).
Ahllu nlm]ilics or lell ve ntricular structure nllll fu nct ion we re very frequent 0 11 baseline
cch(lcard ill~l"i1rhy : 7J. ()'Vohad len vcmrlcularhype rtrophy. 35.5%had lcflventr iculardi latation a nd
14.K'Y.,had systolicdysfunction.
Initial <.'!lX'Smodelswere cunsrructcd10assessnvcmllmnrtality andmortality utter 2 years
(Tah le .1. basic models). In these models lcfl ventricularfractiona l shoncning showed an inverse
llssod;lIiun an d sy~tll ik. dysfunctiou a direct assoc iationwith all-cause mortality. independentlyof
ugc. disbctcs. coronaryurtcrydisease. ang inapectoris,cardiac failure andbasel ine serum albumin.
Fur patients who survived more tll;1112 yc urs. len ventricular muss in dex.ec ce ntricas opposed to
couccmric lcf't ventricular hypertrophy. len ventricularcav ity volume, len vcrnrlcular dilatlltio ll.
thlt:t illl1<l[ shm tcnitll;t nnd systolic dysfun ctionwe re ull associated wilh lute mortality. Systo lic
dys l~ :lIC l illll _ lell ventricular cavity volum e nnd le n ventricularmass werea ll directly correlated
with each oth..'f. \\'hen mcsc J \w ah ks were ikkl'd tug~1t..'f to tl~ I\;t~ ic Cux's 1ll\Q..i . uu ly Ir:l\
ve ntricu la r cavity volumerc l;1iB,:d iLs stariaicnl signilieulll.'C ;n the pn.'\lict;\lIll, fLlh.· mnf1al it .~ .
\Vhcncardiac lOOrtOJ lit)' was ChOS,'llas crd-point tbeCll ncItL~illIL~ w en' \'inll.allr i&:n tkali ll
thosefor all-cause lllOftIl ity: cardiac le ll wntric lllil' rrnctionalshUnCllill1;.o s ystllic \.Ipl'ulk:tillll and.
in additio n, len ve ntricular cavil)' volu me.were associated wilh c:mJiaclIltlt1Ollil)' in alltime rr;III1~'S.
whcrcns lcf ventri cular mass index wa s indcpcmkn!ly ussoci.ncd wijh deeth liner :! y"lIr.l td: lta IMII
shown},
LV GEOMETRY: TII EORETICAI.FRAMEWORK AND I'IHJ( jN<)STI<' IMI'Al"I',
(l'ublcs ~ In 6),
I. V di1::Jtntioll is cu mmonly o bserved in ~all..·s ori V V\I'IIl\~ u\' e rln:1l1 wh ereas pn.··;'illrl·
m rcrlfod lead." pri~ly to an increase in len vcraricu farmass, withnllr lll:1I cavit y ",l lIlI1e . '11IC
Luw of LipIacc. w'L'JCby wall tension is din..ctIy pnlplln iunal III wall r.L1ills arLl illVl'nil.i y
p roportion al io walt jhck ncss, would stll;!'l'St thatan increase in LV wa ll thickness \\1IulJ l~ ~n
a ppropria tc PlYsio logical response to LV uila tnlion, M UIlYpatiellts with I. V dilaw tK"1;llsu haw
increased LVmass (eccentric I.Vhypcnrophy. 22~ Fa ilureIIIincn.':N: I.V mill thic kl)l,.'S.<; m ay h:
pnthlllogica l lx.-cnusc wall tensionincreasesnnd lcac.Is tn illC~lSl..d 1I,\ygell utilizaion. ' 111 i~ may be
revealed on cchocurdiograp hy byan increased lell ventr icularca vity volume lind .1 lew m.tss-Iu·
vo lumera tio, In states of LV pressure overload the rcsuluor increase in wall tension is onset hyun
increase in len vcnmculcr wull thickness. rcl1(,.'Cloo on l'Chnca rdio!!mphy hy hy pertrophy wilh
normal ca vityvolumc teonccmre hype rtrophy 22 ). 'lI'lJ a hi ~h muss-to-volum e t11liu ,
"Dialysis pcticnrs have runny risk fa-tors for bot h LV vol ume rind pressure overload.
Furthermore, theclinical lmportonccof LV hypertrophy may becriticallyeffected by LV geometry.
as has been denumstratcdin essential hypertensive patients (24). Our hypotheses in this study
followod directly Iromtbc [ ': IW ofl.eptacc: wepos tulatedthai inconcentric hypertrophy the majo r
ad v erse prog nustic Impact would be usso clurcd wi th increased LV mass and h igh mass -In-volum e
rat ios . while in states of LVdilatation. an adverse prognosis would heassociated with high cavity
volumelind low mass -In-volume nnios. Ultimately. we speculated thaI in-dept h consideration of
len ventricu lar geom etry wou ld enhance our ab i lity to prognostica te on future adverse events.
l'nricraswith systolic dysfunction wereexcluded from the mortality analyses that follow.
~ Cilnsidercd 3S cont inuous variables, no single ccho ccrdiogmphlc abnorm alities was
ludc pcnderuly associated with ovemll mortality, after adj ustment was made (or baseline age,
diabetes mel litusund ischemic heart diseuse (Table 4. all subjects), ln contrast, both LV mass
tudjuxtcdRR 1,010p er gfm! ) nnd cavity volume (udiustcd RR 1,0 15 per ml/m!) were associated
with l1\lltlilh ty ullcr 2 years.These results werevirtuallyidentical when ccbocardiogrnphic vnlvulnr
disease was added l iS a covariutc : thelatte r covariate had no independent associationwith overall or
lute mortality,
purism!s Wit h Numn l ('w ily Vplnnw Considered as continuo us variables, only LV mass-to-
volumeratio (adjusted HH1.307 perliml) wasind ependently associatedwith mortality in all time
Irmrn..'1>, although lhis trend did notquitereachstatistical significance (Table 4. subjectswithnormal
cav ity volume). Both high LV mass (adju sted RR 1,009per gfm2) and high mass-to-volume ratio
(adj ustedRR l.lil4 per wml) wereassociated with mortality after 2 yearson dialysis therapy. LV
cavity volume was of no prognosticsigniflcanccin this gflll1p. III modelsthat included ullthrcc
parameters. only mass-to-vulumcratio (adjusted RR Utl4 per g/mJ. p '" 11.(76) pl'l.'tlic lcd overall
mortality. while le tt ventricular mass index (adjusted I{I{ I.OO!)per Wlll~' p =: 0.(145) wus thellll l ~
predictor or death alter 2 years. ThL'SC results were virtually idcruknl WhL'1t cchocardiographic
valvular disease was added as a covariate: the latter covariate had no independent nssocuuion wit h
overall crlu te rncrtnlity.
Pnljcnts Wj th I V Dj1i!liltirw. Conside red ns continuous variables. nil single eehuc:m.lillgmphic
parameter showed n statisticallysignificant.independentassociation with ovcrnllmostality {Table
4, subjectswith LV dilatation),In contrast,both hi ~h cavity volume(lldjUSl\.'t1RI{1.0.10 pe r Ull/ll1~)
and low mass-to-volume ratio (adjusted RI{ 0.204 per glml) were strullgly ussrciarcd whh lute
mortality. In models that included all three pammcrcrs, rtn siuglc cchocurdiographic pannuctcr
predicted mortality in all time frames:only len ventricular cavityvolume(adjusted ttR 1.U.l I per
ml/m2• p = 0.001) wasassociated with mortalityafter 2 years. These results were virtually idcnticnl
when echocardiographic valvular diseuse \\InS added as 11 covariate: the Jailer covnriutc had nil
independent associationwith overallor late mortality.
Echocardiogrnphic parameters were assessed as continuous variables ill the H!mly~es
presented above. Assuming a linear relationship between the level til' a given risk fhctur and
subsequent mortality, the potential impact of different variables un late nmrlality call he
convcniently compared by computing the relative risk nf'n sublcctat correspondingpercentiles lilr
each variable. For example. fur patients with normal cavity volumethe 25th and 75th percentiles
for mass index were 116 and 163 respectively, Thc computed relativerisk in this situation w ould he
17
( I.(X,."I"-I . II•• ur 1.524. For mes-to-volemc rat io lhe corresponding figure is 1.6642-71.1.1(". or
1.526. T his sUl.!b'\..",ts thai in puents with rorrn al cavity volume. LV mass indexand mass-to-
VUIUllk:r'.l lins show similarabilites to predict laic mortality. Forsubjects with dilated lc fl ventricl es
.u h;,1~l iIlC . Ihl;ctJrTCs poooing figures was !.X21 for high cavil)' vo l ume :md 2 .675 for lo w mass-to-
vlllume rat io . suggcslin~ tha t nl<Cis·to~VtJIII IIlC ratios may be u more sens itive marker of late
morruliry thun cavny volume.
'lhc previous unulyscsassumed u linear re lationship between the level ora give n risk factor
und suhsI,..qucnt mortality. This assum ption was checked by systematically testing tlilfc rcnl
,licl'kltnnulUScut-offvnlucs in p:UiCIlISw ith normal andd evotedLV cavityvolume. In patients with
nllnn'III,.~lV i ty volume . [Kllicnls with higher LV mass index hal a hil}heradj usted relative risk of
death it'I em-o rrpoints were illCfCaS\.'ll in 10 gfm2 irll:remcnts from 90lhlOOgh 16011m2• tlewcvcr.
increased lute nxlrtality was most cle arly obse rved when LV ITl3SS index \ \-:IS > 12<1 g/m1•
~'1Uh'l k.'11 to 125Wm1 f(Jr mnl~:md 112 I}!m1 for females in ihls eohort(adj ustedRR 3.291. p "
n.1I21)~ Fur n1il~tu-\1IrUI\1C rcuo. ibcrc W;lS a clear increase in late mortality whe n this ratio
exceed ed 1.0 gfml (adjustl-J HR 2.24. p .. 0.041). Forpatients with cavityvol ume > ')0 mllm2 at
haseli ll\'.lm... lIIorta lity jrcrcnscd stepwise wirh rising Cavil)' volume and fallinl} mass-to-volume
nuio. t'llI'ity velumc > 120m l/nl (lU.lj uSh..'\I RR 4 .146, P= 0.01)uud mass-to-volume rat io less than
I. It Indjustcd HR4.27. p " 0.030)were clearlyassociated withanincreased risk oflate mortality .
ANEC I I(X'ARD IOGRAI'IIIC PROGNOSTI C CLASSIFICAT IONSYSTEM(Ta ble S).
Pmicnls were suh.l i vid~" into 4 groups 0111110.' basis of their baseline ecbocardiograms : normal
c:l\'il )' \lllul1le.I. V mass s 120 gfm! (group I.N "" 62l.norma1cavity vclume, LVlJlllSS > 120 g/ m!
IS.
(grour II. N= 1( 5).I.V dilatation. t.v \'u ll1ln~90- 12{) 1l111111~ (gruup III. N '"Nil) uudI.Vdil alation.
LV volume > 120 1I1 1!111~ (gr oup IV. N = 28). Ench gruup was ~ulllpan...d SCp<ll';.lldy to ~111U P I ll'; a
reference category. Aller adjusting fixage. diabetes and ischemicheart llis...as...', the rcl:ll h' c riskIll'
death a fter 2 years was3 .2') (p < O.OUI) for group II. 1.5tr not suuisricullysi~ll i lical\ll Il lT~n'up
111, and 17.14(p < 0.00 1) forGroup [V. Thus patie nts in groups[[ and IV clcnrly had a pOllra
prognosis than those in group I. Lookedat in this way. 193 or3..! patients{57%1with nonuul
systolic function fell into a high-risk ccbocardlogmphic classiflc ntion (II or IV).
We wondered how this LV gco metdc clnssiflcation impacted un mortality ill 11111\.'
expanded multivariate models. applied to all groups (luhlc 5}. includieg patients with systolic
dysfunction.The baseline factors independently associated with nvcrul] nmnnlhy ill Ihese :malyscs
were tlge. diabetes mel litus. cardiac failure :11111 cchocardlographtc systulic dysllll1l.: tilll1. The
association with mortality wasstrongest for cardiac failure, Iolkrwcd hy ugc. diabetes mcllhusami
systolic dysfunct ion.The baseline factors independently predictive of mortality uflcr 2 years were
age, dia betes m ellitus. systolic dysfunction and LV geometry, based UII LV muss am i cnvity
volume. Asjudge d by its lIssociatC1.1 -l value, LV g eometry was the slnlllgcst predictor ul"li,lcl'
mortality, followed by age. diabetes mellitus and systolic dysfunction. III otherwise idcntlcul
models in which both len ventricular hypert rophy(n o/ycs) und lell ve ntricular dilruution ( lllllyc.~)
wereused instea d orthis classification system. only len ventricular d ilautlon was Independently
associated with laic mortality(adj usted RR 1.659. P = ll.04K). withu c2 value '" J.IJlI4. xtmllarly.
whenLV muss index and cavityvolumewere added :IS continuous va riables,only cuvity volume
was independent ly associatedwith late mortalily(RR 1.011, p '" ()JJll). wilh an associated i value
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IIf6.23 1. In a sim ilar mud d inwhich riskwas srati fi c d as I - No hypc nrophy o r dilatation ll >
hyp,:11RJphy. rcrm ulcavity VI.~tIlTl c. III· LV d ilatation. ·i value \\015 4.539 (RR 1.302~:r stratum.
p .. O.lJJ3 ). Ibc prop oscd cJ a.~r.c" lion $1cm. witha 7.: value o f lS.972. was clearl y superi o r inits
ahililY10 pn.,Jict la lc mortn lity ll\;!n co rsdemt ions of m a ss ard vo lere al ore.
Il h'I.'l Ill.'C1lshown in 1.'S.'\l,.'ll lia l h)'l'ICrtcnsivcpat ients that prognosi s cenbe st ratified OIl. : I •
I.V 1' 1ilSS index < 125g1m:!. relative wanrhlckncssc 0.45. 11 - I.V mass indexc 125 Will!. relative
wnl1lhic kn~')i.'i > 0 .45.11I - LVIllass index > 1 2 5 1iIin ~. relative wullfhickncssc 0 .45 11no I V · LV
mass index > 125 gl lll: lind relative wullthic k ncss > 0.457 (24). wc eomparcd thc ability u fl hc 2
dl,,~j 1iC<l t illll sys te ms kl independently predic t differe nt event s in patients free of symptomatic
hlm diseuse al hn scllre . whh rrnction;l Wlrtening> 25 % nn ini tialcchocardiogr;lphy(T llble 6).
Al1.wding tu the s lnndanl cl assifica tion system (25).l hc 246 subj~,1S we n: dis rib utcd es fo ljows :
OnlUfll ~ 2.1.6"10.Gn~ 11 • lH~o. Group I . . _,t4% :mdGroup IV - 3R.6%. U sing the system
(lfIlf'IIlSI.'lJ ill lhi:<i study.~ p.'l icnL~ werc dis rib utcdes follocs : G roup l - 235%. Groupll - 2 3.9%.
(i T\lUplll -oW.II% . GnMJp IV - 7.R% TbcrcwercS2deaths (31 uncr2 yea rs.26cardiac in natUIC)
infhis suhg.mup.In additio n . t111.'I"Cwere 23de nove epi sodes o r ischemicheartdisease (myocardial
infiln:liun ur ang.ina (ll'Cloris ) nnd55 de nom episodeso f eardicc failure, The classiflcaion system
proposed here\\'>15 ilklepcmlcntlynssociatcd with each e vent The geometricclassification pr o perscxl
hy 1(111'\:11 l'l a1.(2 "') showed u statistkal1 y s ii!- Ililicnnt assoc iation with cardiac death and nrt
1.l"'~lId.ll iun hc.11'l.1crilll! lin s tnustical significance with de novo ischemic events. In patients with
S)'1I1plllllat ic cardiac dL'iCUSC atbaselinencithe r classi ficationSYSICll was irdepcndcnilyassoclncd
witllan)"u r thc (l\Itcol11~'S Sludicd(t1at3 notshown}.
ASSOCIATIONS OFECIIOCARDIOGRA PIIi CAI1N()R~ IAIJlI I :S
I' RI:'\\EN T Xl' T3ASEL1 NI ~ (' rank 7 ).
Comparedto patients wilh normalcavityvolumea nd 1.V 1l1:1SSIcs than I:!ng/l11 ~' llati": lIls
w ith mass> 120lVm2 uud normalcavity volume WCI'\: more likely (p < !I,(5)10 be order. diubctic .
have a histo ry orchron ic hype rtension nnd anemia at firs t dialysis : mule genderIp '"'" ll.Ol'1:!) and
ischemicheart disease (p '" 0.07 1)were ofbordcrlincsigni ficuurc in lilisanalysis.
Using patien ts wilhnor umlmnss urn!cav ity volume :ISreferencecatcgury. pat ientswirh I.V
dilatation were more likely (p < 0,05) to beolder. male. to 1101\"1) low initial helllllglohi n :11111hlood
urea levels. and10ha ve higher inorganic phosphate levels: Illw ser um albumin(p """ 0.06:!) le vels
were of bord erline s tati stical s ignifienncc. The independen t assllcia tillilsIll' 111l1fC seve re degree s III
1.V dilatatio n (cavity volume > 120 mllnh we re simila r: ischemic 11I.'al"I disease (Oil 6.7. P
0.038) and wide pulse pressure (OR 1.48, P '" OJ176) were [llsll a ssuciated with lhis abnnrmullty.
Lo w serum a lbumin le vels were unassociacd with more SCVCI'\:l.V dilatatiuu,
Using uuidenticalunulytic stra tegy, systolic d)'sru nctiullOil baseline ccboumliogmphy W:I~
associated with older age. fem ale gender. coronary er tcrydi seaseandlow serum albumin levels.
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ECi IOCAR D10GRAP IIlCABNORMALITIESW I IlLEON DIALYSISTHERAPY
(Tnblcs g to 12).
o r the 432 pa tients who entered into the study. 2911patients remained 0 11 dialysis at one
ycar.fhe re mainder ha vingdied or receiveda rcnaltmnsplant. A to tal of275 patients hada secon d
cchocardiogmm whi le Ull dia lysis therapy. u r ncdien of I ) months followin g the baseline study.
This patient subset was very similarto the parent studypopulation nt baseline. from a clinical and
ccbocrrdiogruphic perspective (Table H). 'Ihe Il)IIll\\'ing po tential predictors of cchocnrdicgrnphic
ubnonuuliry nnthc second cchocnrdiog mm were assesse d : age. gender. diabetes mel litus. ischem ic
heart disease prior to second cchocardi ugmm. as wellas the moun hemoglobin. blood pressure
albumin :IIlU calcium levels. obtained at monthly intervals between the first and secon d
cchocnnllogram.
Hchocurdiographlc Outcome{Tnh!c9). A totalof 245 patien ts hadadequatednra10enab le a
entegoricnl dial;nnsis to bema de ou baseline and lollmv6 up cchocardiogrnphy. II can he seen that
1I10st "'ltie lllS had ubnonml LV structure both"I baseline andon follow-up. although there wa s
qu ile :l hig h degreeo f interchange between nbnonual categories .
Associaliuns u f Echocurdiogruphlc Abnormalities (Tables 10 hi 12). In multip le logistic
n..grcs.~itJn models. in which p.lticlllS wit h normal leli ve n tricles "VCTCused <IS referencecategory
(T:lhlc 10). the presence of' co ncentric hypertrophy was weakly ussochucd with older age and
female gender. LVd iluunionw ith ischemic heart diseuse. nncminand hypertension. whilc systo lic
dysfunction W:lS ussocintcd with previous ischemic he art disease. In s imilar multiple lin ear
reg ression models (Tublc 10). the degree or concen tric LV hypertro phy was associated with older
egc. anemia rind hyperte nsion. the UC!!R.'C of LV dilamion with ischemic 1100a rt diseuse. nncmiu.
hypertension and hypoalb uminemia. whilethedegree nfsyslulie Ilysl"1I1letil11lwas associatedwith
ischcm ic hca rt d i~asc <lnd :lIlclll i Oi .
KI IOCARnl(JG RAI'!-IIC ABNORMALITIES BEFOREAN DAFTERRENAL
TRANSI'1A NTAlION
(Tables13to [5).
102subjects had an cchocurdiogrum within 1 yenr prio r to renalfransplanmtion. as wellas
lIlIlI ther study at an inte rval greater than I year following successful renaltransplantation. Where
Slhjccts had mo rethanon onecchocerdiogram followingtransplantation. the lust study was chosen
[1lr the current study.Selected pre- transplantation chnrnctcristics meshown in Table 13.
Renal Irunsphmtntinn was associated with dmmntic cchocerdiographic changes {Tables14
(Illli [5 ). llo.'Creases lnt.V massind exand cavityvolumeand increases in fractio nal shorteningwere
se n. ·JlR' most dmrnuric observation was the no rmnlizarion of fmctioml shortening in all 12
subjects withsysrollc dys furciion prior to transplantation.
Althllugh :111 cch ocediographic parameters tended to improve. on average. most (76%)
suhjec ts had IIbl111rnml cchocnrdlogr ams til final follow- up . III mult ivariate models. the only
potentially rev ersible factor wns the strong relationship be tween m ean arte rial blood pressure
fidlnwingmmxplnrnntiori andthe failure oflctlventricularhy pe rtrophy tu regress(dulano t shown).
~·l
ISCH EMIC II E,\ RTDI SFI\ SI ~
{lahlcs 1711 11d 18).
BlJ ltDEN <W DISEASE,
22% of patients h'll! Q history of clinicallyupp arcut lschcrrnc lmm ctiscasc ill il1~ql1i\ ' 11 III
d ialysis therapy. 40 01" 337 ( I[,I)"/.» patients freeof ischemic h O:;l11 diSl:;Ise at husdinc were
subsequentlyadmitted forischemicheartdisease whllc on dialysis thcrnpy.
I'ROG NOSIS.
When adjustmentwas made for age and the presence o r nhscnce nf'diahcll'S mcflitux
patientswith ischem ic heart at basel inc were more likely to have systolic t1ysfum:liul1 un rCI'II,'ul
(OR4.36. p =O.004) cchocnrdtography.morc likclym be udmincd Iorrccurrcrncardi;\c Illdllrc (RI{
2 ,03. P = 0.003)while nn d ialysis therapy a nd mnrc likely to d ie early (HR 1.4 8, P 0.026).
Ischemic heartdisease utbasclinc was unassoclarcd with cunccntric LVhy pcnmphy on lilllow'l1j1
cchocardiogmphy a mi de no vo cardiac fhilurej. Must of the irn pnct on mnrtnlify was vi" lilt'
occurrence of cardiac failure: in a siuularproguosticmo ddthat nt so includedcard iac iaiturc ,IS a
covariate. ischemic he artdisease \\ 'IS no hll1~c r lndcpcndcnuyesochucd with numullty.
ASSOCIATIONS(Tables 17andI8 ),
In stepwise logistic regressio n models (Teblc 17), patien ts slarting E."iR D therapy whh
ischemic heart disease were more likely 10 older. diabetic, less anemic and 10 haw sy s tulk
dysfunction oninitia l cchoca rd logram .
Using the Cox's model (r uble 1&).applied to subjects without ischemic heart disease at
hasclinc, thc independent predictors of new ischemic heart disease were : at baseline • older age.
diabetes. xrrmkjnp,und in particular, the presence of concentric LV hypertrophy, LV dilatation or
systolic dysfunction Oil baselineechocunfiogruphy: while on dialysis therapy- hypertension Hnd
hypoalbuminemia.
CARDIAC FAILURE [Tables lQ10 ~ I }.
BURDENOF DISEASE
31'I. of all patients had a history of cardiac failure ill Ihe time of illl\.jlIiUI\ uf diil l ~'sis
therap y, O f these 133 patients 75 (56,4% ) went on 10 have ill lea"llI lk." clinicnl recurrcncc \,h ill' Ill'
dialysis therapy. Of the 299 pi\tielll~ Ircc uf cardiac failure illllil'iClinc, 7(1125..1%)hill!nn Cpistllie tlf
ucw-onsct cnrdiec failure while Oil diill)"!iis therapy.
I'ROCiNOS1S
Cardiac failureIII baseline curried a very poor prognosis. 1'atients with curdinc failure ltil"!l
2.6 limes more quickly than those without cardiac failure (p < lI.nom ). ,\ Ilel' adjustment IiII'
baseline age. diabetes end ischemic heart disease using the 0 .'< lIIudel. tbc eXCL'S." mllr1alil)'
remained VCr) ' high (RR 1.93. p < OJ)()I) .
ASSOCIAnONS (TahIL"!> 19 and 20).
Using logistic l'I..gression analysis [Table 19). the illllc('lL'OIlent disa;:rimin:lling char:lCh.';stk s
of patients with baseline cardiac failure 'w re older age. diah:IL"Smellitus. ischemi c he art disc"....:
and tbc presence of LV dilatationor systolic dysfunctionon ha.'iClir-..: L'ChucimlitlW'llphy.
Using (he Cox model {Teblc 20). the independent predictors III' de llllVII cardiac lililllfe
among those free fro m the condition lit baseline were: lit b aseline • older llge ruul the pvscncc l1f
concentric LV hypertrophy. LV dilatation or systolic dysfunction: while on dialy sis therapy •
anemia. hypoalbuminemia and hypertension.
The independent predictorsof recurrent cardiac failure (TlIble 21) " 'Crt.: ischemic heart
diseaseat baseline. as well as anemia and hypoalbuminemia (p c 0.1)(1) while on dialysis Ihero1py.
"TIlE IMPACT OFANEMIA(Tables 22(0 24).
I,EVELS 0 13SERVED AND ASSOCIATIONS{Tllhlc 22),
The ll1CUIl hemoglobin level while on dial ysis was 89 ± 15 gil. higher in per itonea l dia lysis
(96 ± 15 gi l) than hem odialysis patients (84 :l: 14 gil. p < O.OOO I). The mean t ransfus ion rate during
the study was 5.2 ± 7.5 transfusions per yea r. Ery thropoietin was first used in this pa tients sa mple
in 1989. 26% of'puricnrsreceived erythropoietin at somestage during thestudy.
We divided patients into 4 time intervals acco rd ing to year of study entry : 1982 · 1984
(2fJ.)%), 19115· 19116 (17.3%). 19S7 · 1988 (27.5%) and 1989 · 1991 (34.9%). Mean hemoglobin
lcvcls . K4± 16. ilK ± 19. 119 ± 16and91 ± 12 (p for trend 0.003)- ruse progressively with year of
study entry. as did the proportion of p atientsreceiving erythropoietin - 10.2%. 23.0%. 22.0'Yu and
4 1.2%' ([1fo r trend0.(4 ). '111C 1111.:3n hemoglobin levels observed were not u functio n of time spell!
ou diulysis therapy.
We divided patients according to tcrtilcof meanhemoglobin level [Table 22). Patientswith
adverse prognostic features ;11baseline• diabetes. ischemic heart disease end cardiac failure- were
maintainedat higher hemoglobinlevels.
PROGNOSTIC IMPACTor ANEMIA {Tnblcs23 and 24).
Alier adjustment for baseline age. diabetes, ischemic heart disease as well blood pressure
und serum ulluauin levels measured serially. anemia was independently associated with the
lilll11wing outcomes : LV dilatation on follo w-up cchocnrdiography. de 110V O cardiac failure.
recurrent cardiac failure rind death. [I wasalso independentlyassociated with systolic dysfllilelitlll
on follow-upcchocardiographyin hemodialysis patients.
Til E IMPACT OF IIYPERTENSION fTohlcs 25 IIJ 28).
I .EVELSOBSERVED AND ASSOCIATIONS (Table 25).
111C average mcun uncrful blood pressure level while on dialy sis was 101 ± 11 mmllg.
similar in pcrhoncal dial ysis (101 ± II nun Jig) and hemodialysis patients 102 ± I I mm Ilg. P =
CUS). On average patients re ceived 1.2 ± 2.1 antihypertensive medicat ions while 011 dialysi s
therapy (lfJth percentile - zero. median- O.9.l){)th percentile -3.0). Ca lcium channel bloc kers (3.14 7
p nticnt mnnths) were the most frequently used agent. followed by beta blockers (2.707 patient
l1lo n tl1.~ ). AC E-inhihilo ["S (1.546 patient mon ths). vasodilator s (1.457 patient mo nths) und ccutmlly
aCling agents (520 p atient months).
We divided patients into 4 time intervals llct'urding ttl ycur of study entry: 19111 - 19t14
12lJ.J% ). IIJXS - IIJX(, (17.3%).19117· 19118 (27.5%) and 19119 - 1991 (34.9'VD). Mean arterial blood
pressure leve ls - ]()J ± 9. lUI ± 10. 101± 12 and 101 ± II <p for trend 0.42) were sim ilar in the
11mI'lime pc:rintls. The mean uncrinl blood press ure levels observed were nut a funct ion of tirnc
spcut on dialysisthcmpy.
We divided patien ts according to tert ilc of mean arterial blood pressure level (Table 25) .
Patients with adve rse prognostic features at base line - older ngc. ischem ic heart diseas e. cardiac
failure lllll1hypoalbuminemia- exhibited lowe r mean arterial blood pressure level s.
PROGNOSTICIMPACT OF
MEAN ARTERIAL Bl.OOD PRESS URE LEVELS (Tables 26 to 2R).
All er udjustmcnt lin baseline age. diabetes. ischemic heart disease as well as hemog lobin
lind serum utbunun levels measured seria lly, higher mean arterial blood pre ssure levels wen:
."
ind...-p.'TIdently associatedwith ibc following outcomcs : c·ul1l"\·nlric I.V h~T".'t1l\'PhY. LV dikuution,
increased mass index and cavity volume on follow-up c~rn.ll,:;Jnlitlgrarhy. lie 1111\"11 isch.:mic heart
disease. and de novo cardiac failure.
Paradoxically. low. not high. 3 \ '\.T.lJ,.'C mean artl.'riill hltll,-.] pressure k n-Is were ;t..;..... ..:ial"'\1
with mortality. II is likely that jhis observation rcrlc-ctcdthc occurrencetil' cardiac failurepri,... hi
dCOI,h: (15%of all deaths in dialysis p atients were preccd ...d by an cpisndl,' of c••rdiac failure: menu
uncriul blond pressureleve ls 1~1I from 103 ± 10 mm Ilg bdhrl.' In IJK 1: 1J nun Hg II' '' (Ul Unl )
following the occurrence of curdincla ilure. Among patients ndrniucdfor cerdlac fuilurc white on
dialysis therapy. low blood pres sure was the majnr inJcl"CIIl.km prcdiciorIIf death l atl.ill .~l l,.'ll I{ I{
1.43 pc...10 mm I-Ig rail in mC311 ancrial blood pres sure. P< lUlUI ).
J]
Ti lE IMPACT OF IIYrOAUl UMINEMIA (Tables 29 to 31)
LEVELS OBSERVEDAND ASSOCIATIONS(Tablll29)
The mean serum albumin level while on dialysis therapy W;)S 37 ± 15 gil. higher in
hemodialysis(39 ± 5 gIl) than peritoneal dialysis patients (35± 5 gil. P < 0.0001). There were 110
diffcrenccs in mean serum albumin levelaccording to year of entry into studyor according to lime
spcnron dlalysis thcmpy.
One third ofpnticnts had mean serum albumin levels less than or equal to 36 gil. one third
between36 und 39 gil und one third had levels greater 39 gIl. The characteristics of patients in the
different tcnilcs are shewn in Table 29. Patients with lower albumin levels while 0 11 dialysis
therapy hadmlvcrscprognostic features :11hascline , older age (p ""0.0002), diabetes (p : 0.0005)
und ischemic heart disease(p: 0.( 2).
PROGNOSTIC IMPACT OF IIVPOALIlUMINEMIA (Tnhlcs30 und 3 1).
A Hcr lllUustlllCll1for HgC. diab etes and ischemic heart disease at baseline. as well as mean
urtcrinl bloodpressure levels and hemoglobin levels while on dialysis therapy. hypoalbuminemia
was independently associated with each of the following outcomes: LV dilatation O il follow-up
cchocardiog mphy, dc novocardiacfailure. recurrent cardiac failure. de novo ischemic heart disease.
cardiacmortnllty.non-cardiac mortality andoverall mortality.
ABNORMALITIESOF CALCIU1I.1·Pl lo SPll t\ 'm Ilt )MEO:-iTASIS (Tabll'lO ~) 111 3 1).
l.EV ELS OBSERVED,
22.6DI. of patients h.1d mean calcium levels below 2.2 nmklill ( I ~UI'Y. in III) vs. 21}.9%. in
PD. p " 0.(08 ). All er adjustmcnt for mean serum alhumin levels. ll M::ln c:llcium lew ls we re below
2.2 mmolll in 9 .0% (11.7% in 110 vs. 5.5D; . in I' D. p = 11.lB).
'11Crc was no impm:t of study crary period Oil mean calcium. phosphorus or alkaline
phosphatase levels. The pcrccntugcs with hyprcakcmia were 211% for paticnts enrolled lip III (1)114
(N- 1l4). 23% lor 19115 to 19116 (N- 74). 26% for 19117 In IIJHII IN"' IIH) and 22% li'r l'lilticlll!'l
enrolled from 1989 tin (N=14R) (p=0.79). For high mean illtl~i1 l1 i c phusphllnls levels the
corresponding figures were 43%. 45%. 49% and 43% {p=O.72I. Fur high :t1kulille phusphatil"C
levels Ihc figures were 30%. 24%. 25% and 22% (p=0.591. 'l1lCTC wnx a clear a.·;.'iI lCialiuu!lt.1\\'c'C1l
time on dia:ysis and calcium levels: in patients wilh I1lC<In seru m calcium levels les s than 2.2
mmolll.40% were on dialysis s l year. 32% WCfC on dialysis I to S2 years, 14% were IIll dialysi!'l2
to 3 years. 8% were on dialysis 3to S 4 lind 4% were on dialysis > 4 yc:lt~ (p = lJ.lIlKII ). 4J .I)% Il:kl
inorganic phosphorus levels l;rcater than 1.9 mmolll (51,6'"1., in Ill> \'s, 3~ . 1% ill I'll. P -- lUNIII.
24% had alkalinephosphatase levels g.reater rhan 120 UII (23.lJ% in 110 vs. 211, lJ% ill I'D. P '" 0 ,,1(,).
There\ \lUS no relationship betwe n meaninorganic phosphorus and alkaline phospluunsclevels ami
time on dialysis therapy.
PROGNOSTIC IMPACT OFCALCIUM. 1'1IOSI'IIATE AND
ALKALINE PIlOSPi lATASE LEVELS (Tuhles 32 and 33)
3l
On un ivariate a na lysis. ap plied [0 the entire co hort. patients with mean serum ca lcium levels
hc!ow 2,2 mmol/l had a relativerisk of death 2.90 <p< o.mll) limes that of patients with values
"how 2.2 mmol/l. Alkaline phosphatase levelsabove 120 tJll (RR 1.63. P = 0.0(4) were also
US SOdll t l"l.1with early mortality. while inorganic phosphorus levels had no impact. The impac t of
hUlh lowmeancalciumlevels and highalkalinephosphatase levels persistedwhenadjustment was
mudc lilT multiple possible confounding factors. including mean serum albumin level. The
conclusions we re ident ical when albumin -adjus ted calcium was instead o f actun1 calcium levels in
similar 11111111":lrl:1Ic models. Ilypocalccmia retained its independent prognostic significance in
patients treated predominantly w ith hemodialysis and in patients treated with peritoneal dialysis.
Adding I11C,I11 lntcrdirdytic weig ht gain as 11 covariate had no impact on the results obtained in
hcmodiulysis paticnts.. lIigh phosphorus levels were of prognostic significancein neither group.
Iligh alkaline pbusphatuselevels were nfhonlcrline statistical significance in hemodialysispatients
nnly (mljusted RR 1.7S. r '"(},{163).
In uthcrwisc-idcmical analyses in whichmean calcium. phosphorus.ulkaline phosphatase.
albumin. hemoglobin nnd mean arterial blood pressure levels were included as timc-dcpcndcrn
cnvurlutcs. h) pocnlccmia was independently associated with mortality in the overall group
(lllljustl"l] Hit 1.::1I. r = ll.OM ). in hemodialysis pati ents (adjusted RR 1.33. P "" 0.005) and in
pcriIUIl\':ll dialysis patients (adjusted RR 1.36. p '" 0.028). In these analyses. high alkaline
pll\lsphatm>elevels were associated with mortality in the combined group or hemodialysis and
peri toneal di:llysi-e pll ients (udjustcd RR 1.13. r = 0.0 19). end in hemodialysis patients alone
(adjusted RR 1.18. P '" 0.(40). but were not associatedwith mortality in peritonealdi:ll)'sis patients
alone. High phosphorus levels had no impact on ll10rtnlity in these model s.
Using Cox's regression analysis. calcium levels below 2.2 mmol/l were assnciall'tl with
each of the following outcomes: de novo ischemic heart disease (adjustcd RR 5.23. 1 llf l ).
recurrent ischemic heart disease (adjus ted RR 2,46. P '" (l'(lO6), de nuvu cardiac failure (ndjuxtcd
RR 2.64. p < 10-1) and recurrent cardiac failure (adjusted RR 3.)0. r< 10-11. High phnsphnrlls
levels and high alkaline phosphatase levels had no independent uxsocintlnn with any of these
outcomes.
ln otherwise-identicalanalyses in which mean calcium. phosphorus. ulknlinc phosphatase.
albumin. hemoglobin and mean arterial blood pressure levels were lncludcd as tunc-dependent
covariutes. hypocalcemia was independently associated with de novn ischemic heart diseuse
(adjustcd RR 1.49. p ""0.025). de novo congestive heart failure (ndjusll.'!I PI{ lJ4. r ""Il.OlO)und
recurrentcongestive heart failure (adjusted RR 1.31. p '" (l.03R). lIigh mean inorganic phosphorus
andalkaline phosphatase levelshad no association withany of'thcsc \IUtCI1I11CS.
as
DISCUSSION
I.EFT VENTRICULAR ABNORMALITIES IN ESRD
DIAGNOSIS. Echocardiogmphy has been the rncst widely-used cardiac non-invasive ca rdiac
imaging lest in the general population. because of accuracy. simplicity. lack of radiation and
relatively low cos t (25). In the general population, lcll ventricular mess. measured by
cchocnrdiogruphy, is a stronger predictor orcardiovascular morbidity than blood Pl'CSSurCor other
classical risk factors. with the exception of age; this has been shown in patients with hypertension.
in p atients with UT without nngiographiculty determined coronary artery disease or heart failure. as
well :1S in the general population (24.26.27,2R,29,30,31.32).
In dialysis patients. Mrnode cchocnrdiography has been shown to have high reliability and
valid ity (33). Ventricular diameters. however. increase with Fluid rcaccumulatlcn follo wing
dialysis.as line would expect: this effects the calculated len ventricular mass index (33). A practical
consequence or this observation is that the time period when the study is perfor med and lluid gains
need til he standardized in cchocardiogruphicstudies on dialysis patients. In our current studies.
cchecardiogmmsare carried out the day after a hemodialysis session. with the patient at dry weight
and a mnxhuum allowable weight gain of I kg following the dialysis session. Theassessment of
dry weight. frequently defined as the weight at the termination of dialysis below which the patient
is likely tn become hypotensive (34) is problematic in dialysis patients; none of the
cchocurdtcgmphic studies on ESRD patients have employed methods (such actual central venous
pressure measurement or non-invasive techniques such us bioimpedance monitoring or inferior
vena caval ccbocardiogmpby (35.36.37» that accurately measure blood volume. In practical terms.
Jh
the impact ofh ypervolemiaon calculatednmssindexis small.of theorderoft) tPlll ~ li.lTeach litre
of fluid accumulated (33); this observation partially reflects the fact that bnth the numerator
(calculatedmass)and thc denominator (calculatedbody surfacearea) used to calculate 1ll,ISS index
(mass/surface area) tend to increase in pnrnllcl with Iluidaccumulation.
nURDEN OF DISEASE.Abnormalities of cardiacstructureor functionnrc very much the rule in
ESRD patients. In our study we defined systolic dysfunction as cchocardiographic rmclll11 I,11
shortening S 25%. left ventricular dilntationns cavity volume > t)() 1111/1l1~ (20). and len ventricular
hypertrophy as mass index > 13\ WI11~ in males und > IOU g111l~ in females (21). On bnscliuc
cchocnrdiography only 14.8% of patients had n0n111l1 len ventricles: 14.WY., had systolic
dysfunction: 39.0% had hypertrophy with normalcavity volume (vcouccntric hypertrophy"(221:
27% had kit ventriculardilatation: among [l<ltientswith 11.'1\ vcntriculnrdihuuuunf!f!'YDulso had lell
ventricularhypertrophy (vccccntrichypertrophy"(22». Several cross-scctlonatstudies haveshowna
highprevalenceoflell ventricular ubnormafitiesin ESRD patients (1I.12.13.3K.3I).40.4 1.42.43).
RISK FACTORS. Left ventricular abnormalities can occur in response to hoth LV volume
overload and pressureoverload. LV volumeoverloadlendsto prclifcnuionof snrcuncrcs in series.
chamberdilatation and augmentedcardiac output (44). In this situation, the tradeniTli,r increased
LV volume is nn increased wall tension (and oxygen consumption). by the Law ti l' Li.ptac
(Tension> Pressure x Rndiusl2Wali Thickness). In situations of pressure overloud.sarcomcrcs
proliferate in parallel with existing sa rc OJ1W TCS. leading to wall thickening. lending tu increased
cavity pressure.This increasedcavity pressureallowscardiacourputro bemaintained. Thetradeoff
in this situation is increased wall stiffness (44). ESRD arc exposed ttl many factors leading III
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v olumetlvcrlll:W. such a.. anemia. anencvcoous conocctionsand chronic Huidoverload. They arc
ilisci fn.'tjlll,.'fltly expescd to rad on; which lead to pressure overlood. such as hypertension and
1Ic:c.1..ionallyuonic stenosis,
In this study. the independent associations of systolic dysfunction on baseline
l.oc hclCilnliugmphy wen: older ugc, femalegender. coronary artery disease and hypoalbuminemia.
Oil rcpeu cchocardiogmphy, l3 months lutcr. the independent associations 'VCTC ischemic heart
diseuse Will anemia. LV dilauuion atbnsclinc (with normal systolic Il urction] was associated with
older age. male gender. anemia low blood urea levels and high inorganic phosphorus levels. LV
lli1:IWtiul1till Il)IJUW-Up ccboca rdiogmphy wasassociatedwith ischemic heartdisease.hypertension.
lltll.'tllii. ;uk!hyroaUmmincmia. ConcentricLV hypertrophy wasassociatedwitholder age. diabetes
mellitus. chronic hypertensionand anemiaal baseline"On follow-up ccboccrdtography. concentric
I.V hypertrophy W"U." inul'fll-ndl."fttly associated with older age. hypertcnsion. female gcntkr antI
Olli:w..ia. It is WI)"likely that anem ia is a major playi.'f in the cardiacabnormalitiessee n in ESRD.
Scwn lll-pillcmiulo1:!ical surveys, includingthc current smdy (15) have suggested thai anemia lead s
til Idl ventricular dihuanon amJlor left ventriculardilatation (11.14.41). There have been several
sludi.:s Ihal luwc exmulucd the effect of partial correctionof rcnaluncmiu witlr rccombinam human
erythropoietin (rl luEpll) on locho<:lIrtlingmphie abnormalities. Most of these studies have included
small Il um\ll:rs \\f patients. and have compared mass before end after rHuEpo therapy. in the
,IIlSClKI: til" mt untreated control grou p. In spite (If these limitations. the studies have shown that
In.:-.Iting anemia leeds III a decrease in hypoxia- induced vasodilatation, an increased peripheral
resistance. reducedcardiac output. and partialreversaltil' lctl ventriculardihuution.uul h ~l"-'111\lll hy
(45.46.47.38.49.50.51.52.53.54.55.56.57). None Ill' the published litcrutun.. to Jail: has mk"'lU:ll~'
patient numbers and follow-up to lest the hypothesis that improvement til' whocurdiugrnphic
parameters will reducecardiac morbidity or mortality. To date. there h:ISb.:C11 1111 study til 'lSSCSS the
risks and benefits of comple te normalization Ill' hematocrit in ESRI> puticnts. Th~' studies
completed to date have shown that p artialcorrection or uncmlu leads to nnly partial revers al Ill'
cchocardiographic nbnormnlitics. Whether complete correction of' anemia lends III further
regression or these nbno rmnlitics. and the cost of such ;111 upprouch in terms til' lil\anc~·s.
hypertension (58.59). seizures (58.59). ami access loss f5K.60.1lI.62.6J.(14) is currently llllknmvn.
One study showed thnt hypertension abrogated the impact or uncmia correction (Ill len vcntriculur
hypertrophy (65) .
Al't' gnd Gender Several studies. including the current study (IS) . have implicated ngc as u risk
factor for cchoeardiogmphic ebnormalitics in ESIUJ (31).fl6,67). There lire nn data fr omlither
investigators. 10 dare. to suggest that gender influences the development of c:lfdillillynpathy in
ESRD. In tile normal pop ulation, the effects of ageing include an increase ill myocyte sil l.'.
increased rule of degenerative change. fibrosis, loss or myoctycs . amylnidusis mul culcitlcurkm
(68.69). The specificeffects of age on the uremic heartare unknown.
~ Severalstudies have shown that len ventricular hypertrophy is conunoucr in ESJ{[J
patients with hypertension (14.15.67). In general. the corrchnion between len ventricular
hypertrophy nnd blood pressure has been relatively weak. For example. in the study oj"<in:"ves uud
co-workers. variability in systolic blood pressure could explain 10,3% Ill' the vuriahilltyin leli
ventricularposterior ",1 111 thickness.whilevariabilityin diastolic blood pressurecould explain6.7%
of the varinhllity in len ventricular wall thickness (14). The current study clearly shows that
hY(1CJ1ensi(111 isassociatedwith I,V ventricular nbnormnlitics in end-stagerenaldiseasepatients.
lli~ There is evidence lor n specific diubctlc card iomyopathy in dia betic patients
withuut ES I{f) . This is usuallymanifestedby len ventriculardiastolic dysfunction.inthe absence
of lilrb!e vessel disease. and may be associated with microvascular coronary disease
(7lJ.71.72.73.7.j.75.7(1.77.7KI. I.eft ventricular hypertrophy is found more frequently ill
hypertensive diabetics thun hypertensive non-diabetics (76.77). In tI post-mortem study.
hypertensiv e-diabetic heartswere heavierand had more fibrosis than diabetic-non-hypertensive and
hypertensive-non-diabetic hearts(7K). We found unassociation betweenconcentriclen ventricular
hypertrophyanddiubctcs. while Greaves and co-workersfoundan association withthe presence of
diahetiencphr oputhyand len ventricular hypcrtmphyf 14).
l:ich~·mi :. It is well knownthat poor systolic function is IImniorcomplicarlonand is
lhc principal determinant of outcome li.l liowing. myocnrdial infarction, In our patient cohort(IS) as
well as in the cross-scctionul study or Greaves and co-workers([4). patients with u history or
Illyllcimlial illl:m:lioll were much I1 Wt'C likely 10 have cchocardiogruphic systolic dysfunction.
l\ ll l~'~'el!eJ1 t ischemicheart disease\\US independently ussociatedwith
Urc.11lioulllil...Mil1J.ru1ri.ili.!u 'there is direct evidence Irorn animalstudies 10suggestthat the uremic
cnvinuuucnt is dcrrlmcnrulrothe myocardium. Induction of uremia in Sprague-Dawley rats leads
Iu increasedeposition Ilf illterstitial ground substance. followed by collagen deposition. as well as a
reduction in capillary surface density. These effects appear to be independent of blood pressure
(79.80). Uremic serum is a direct myocardial dcprcss nm (N1.N::n. '1111: specific factors n:spollsihlc
furIhis effec t have not been identified. Some authors believe that thedepressant factorsurc water
soluble and filterable.with aruotccularweight between HJ.OOOand JIl.OOOd;lltuns (N.l).
There is indirect evidence thnt urcru ia is cardiotoxic in hU1\1:1IIESRll . In the NationalCIl-Olll:rali\'l.'
Dialysis Study there were more clinically hnporunu cardiac cvcrns in r al icllls w ho were
randomized 10 receive less intensive dialysis (84). In chronic renal failure kll vcutriculnr
echocardiographic ubnurmaliticsnrc commoner indialysispatients thnnin prcdiulysis patienls (14).
Churchill andco-workers round that more intensive dialysis nrncfiorutcd cardiac ahnormalitk.s in a
rnndomized crossovc r triul (85).
Renaltrunspluutution isncouvcnlcnt. though cxrrcme. natural experimclll that allowsoneh .
assess the impact or uremia. There have Peen n numbe r (II' C: ISC reports IhlClIlll"'llling dramatic
improvements in cardiac function in patients with severedilated cardiumyupathy11l(l.In ). IIImil"
study. a totalof 102patients had an ccl . cardiogramwithin1year priortu tnmsphmtution as wellas
n year or more following trnusplantation, In thispopulntion. which \ViIS largely tree 01" cnnmnry
arterydiseasethe following changes wereobscrved: lell ventricular mass index Icll fhnu 175 ~'ml
10148 g/nl(p <0.0001); le ft vcnrrtc utar ccvny volumcrell from llfll1ll/nl til 77 m l/m1lp .,.., O.IIIIJ);
!ell ventricular fractional short ening rose from 35% III37'YQ (p '" tJ.()]6). Multivariate m11l I y s i.~
suggested thntpatients with high len ventricularmass index prior tn tnmsphnuntionand those with
better blood pressure control follo wing trcnsplununionwere most likely 10 have a lll ll ill leli
vcnmcular mass index. The must dramatic changes wereseen in the 12 p:lticnlswith systolic
dysfunction (fractional shortening less than 25%) immediately prim to transplanuninn. Systolic
dysfunction reversed in nllthcse patients.with fractional shorteningincreasing from a mean01'22%
til 34%,(p -c OJlllO l), Thesedata suggest that rena l trunsplantetiencan have a profound imp-let on
dlkncd cnrdiomjepathy, at least in pntic rns without coronary artery d isease. Indirectly. the refore,
lhese datllsuggcsru role loruremia inthe pathogcncslsct'urcmic cardiomyopathy.
IJypcrpamthyroidismis a l11l\j or co mponent of ESRD and the uremicsynd rome. Fhccurrent
study wnsunable to directly res t the hy pothesis that hypcrpamth yroidisrn is a 11l[~O I" etiolugical
Iactur intIl\." ucvclopmclll llf uremie c'Jr(.liom yopalhy. asother authorshave suggestl,j (88),
11 is Iltll ckar how mnlmaraion might lea d 10 curdiomyoprahy in dilll)'sis pmicuts ,
Maln utrition e;m have pronounced effects 011 cardiac s tructure a nd function in non -uremic
indiv iduals, For example. ' brown :llrophy" ctthc heartwas seen in aut opsy st udies {If individuals
whu died of starvation in thc Wa rsaw ghetto in World War II (89). Low cardiac outp ut. cardiac
lihrnsis. Hilly infifuationnud myofihrilhtra trnphyleading10 l"rnnkcardiac failure have been seen in
indiv iduals with kwashiorkor (90.92 ),l1oth cardiac atrophyand cardiac hypertrophy (93 );lreseen
in llla rusmus. The diets ormany ESRDpat ientssho w similar ities10those thatresult in kwashiorkor
(inadequateproteinintake. with adequate caloric intake)und marasmus(fuedcquutcintake of roth
protein mill calories). In thisstudy serialalbumin levels were inversely associutcd ·...ith the extentof
LVdilatnrion ill hemodialysisp atientsand the presenceufconccnuic LV hypertrophy in pcrhoncul
dialys is patien ts onfbllow-upcchocardicgmphy . Th e vastmajority of ESRD pa t ients already have
lel vcrariculnr uhnormnlitics ll\ the time Ihey startd ialysistherapy (15). Verylarge patientnumbers
whh Itlllg-Icrm Ihllo' v-up. would be needed to show that low albumin levels predate the
deve lopment o f I.Vnbnormnlitics in patients fl\'e of LV abnormalities at baseline.
e!'ROGNOSIS, There has 1lI.-":1l ,"cry link prospect iveresearch 1111 Ih ...• Ilmgl\\)sl il' impa ct Ill'
left ventricular abnor malities in ESRD patients . although Sil1~rbcrg et nl. (9·11 s!l\. \\"\'ll a StHl1g.
independent relationshipbetween left v e ntricula r hypertrophyand s uhscqucnt llhlrlality on dialysis
therap y. In this stu dy systo lic dysfunction on hnsclinc eehncmdillgmphy \\ ilS imlcpend cntly
associetcd with the subsequent development o r dc novo bcucuuc heart disc;lse, de 1IU1'" card iac
fai lureand death. The prognostic lmpacrotlcn ventricular index and cavity volume \\1IScriticullr
dependent on the undcrlyingSlateof the lell ventricle: mass indexW ;lS (II'pnlgnustic i mp;lel Ilill y in
those without left ventricular dilatation: mass index was Ill' no prtJgl1llstic impac t in till.' 1allcr
patients - in these patients Iell ventricular cavi ty volume was the critica l pl'Ilgllo slie vnriuhlc.
Lo oked nt in this \\11)'. it W;lS clear thaI subclmica! ubnormaluicsor the len v....ntricle were
har bingers of ischemic heart discasc. cardiac failure and t1cath. even ill th e ahscl1l:cof systolic
dy sfunction.
IS CHEMIC IIEART DISEAS E INESRD
1>IA(iN(ISIS . Inmechanical te rms.myocardial ischemia could be the result o f disorde rs nt several
level s : large und medium s ize arterial disease (including luminal narrowing and/or inability to
di lute when required]: small ve ssel disease: all i rmppropric tcly sma ll density ofvasc u lur channels
relat iveto m yocardlulmasx Ischemia ccnnlso UCCUI" in th e absence mechanical problem s, if blood
is delivered 100 slowly, has Inndeq uatc nutrie nts 1i.} 1" energy production. or the lIlyucnrc.Jial
machinery for cnergy production is Inadequate even thctgh s uhstmtc delivery is udcquntc.
Adcqumcsc resuy mechanisms arc needed Iormyocar dinl ischemia to bepercei vedas pain,
Ischemic heart diseuse is nula homngcuco usentity . espec ially inESR D patients . Atleast 4
J:H.:tun:J11<lkc rhc dcfin cntlon ofthe natural history or tscbcmtc bcnrt diseasediffi cult:
I, Man}'ESHD pnticnrshave nnn-uthcrosckmtic ischemic heartdisease.with typical symptoms of
ang inapectori s hut patentcoronal)' arterie s (1)5.96 .97). For example Rostandand co-wo rkersfound
[hut ahnut 25 % Ill' patientswith typical unginel symptoms hndeither no disease or trivial disease on
coronary arteriography. ·[1ICSo.: patients were more likely 10 beAfrican-Ame rican, an e mic and to
hnv,.. severe lcfl vcntr icnlar hypertrophy (% .97).
~ . II is 111.'il,1 knuwnthatmany ES1{f)puticuts with advanced ursucmicalcoronuryartery stenosis arc
lIsymptmnatic. without typical electrocardiographic changes. The reported frequen cy of sil ent
isc hemia in ESRD patients(diagnosed hy c nt irmousST segment monltoringj, seen most of ten
dnri ng. orjust ..Ocr.dialysis. rangesfrom 15 1037 %( 98.99.100,101. 102),
3. The llOl1-invnsh'C tl."SIS used 10 di.~oosc ceronarv anery t.l iSl.~ in tl1l.· ~'<:ncr.d J'llIpu latirott arc
problematic: in dial)'Si5 p:1timts. Creatinine pb.lSrmoki~. including its Mn rr:.l1.1i"n, .tIlJ b.:la ll.·
dch}'drogcnasc J,...·ds arc clc\-atcd in renal lailurc. wh ichnm kl."!\ l'-: Ji:I~I'lllSis of ,11.11\\' nl}"IIt.~II\Ii'11
infarct ion more dillkult (10).104 ). ·[k lirnitcddatu l."Il1'1l:Cmina;th,,: usc Ilf slrc~s k."Sl ing ill ESR I)
ratiel1ts haveg enerally beendi!iUJ'lpointing . '/11,,:physical c tlllditillil ti l' Il\ ,Uly FSIUJ (XUiclllS,the
frequent uscof drugs effectingheart rare.a nd the Ih•.cqucntoccurrence I,flklll-Srx'l.:itic ST Sl'~IIlCl t t
changes limit the usefulnessof s tandard exercise stress tcsting illES I~ J) l11lliclllS, f{l1staml wil \.'11-
workers. forexample. repor tedthat 80";" o f r:~RD pa tientsIn ibl Inreach IIl,l!"ge l hem ra te ofH5%
ofpredictedmaximum (97).11Ic useof'dip yridamol c and do huraninc :L~ 1:I rcss ingllgCI11:i. 'Ulll lllc
lISC of other diagnoslic 11.'CIVliqu\.'So stich ,L~ l"l:ho c:udillg n lphy III t."-'ll....1 rcg iult d wal t mllti" n
ahoon llal itics. or tha llium scint ij!raphy have s1.1\\11 mixed n..'l>lllts in F,SRI> J\lticl1ls
(10.1.105.106. 107.108.1(9) and cannot yet be fully f,.'llIklrs,:d. Largcr slutli\.'S are lIt.-cd clL where
selec t ion bas is minimised.ant.! palienlSa rc slralilk-x1byt1ia h...1icsl a i ll " and SYl11phUlls n r i!dlcl11ic
bcart d iscase,
RISK FAITO RS FOR ISCIIEMIC IIEART m~EI\SE IN ESRJ). 20% uf lhe T"ltk'nt 1,,'111. ," we
studies \VCfC ad mitted with nn e pisodeof ischemic ht."<lIl. disca~. (anginu p.-cturis. ctlru narynrtc ry
rcvescu lariza tion or myocerd!el infarction) while on dialysis tbc...jpy. llalfof these episodes were
tic novo episode s. in patientsw ho had not had ischemicheart diseuse lit ibc inception (II"di,llysi s
ihcmpy. The independent associations o f baseli ne ischemic heart discasc included older ugc.
diabetes, ec hc cardiogra phic sy s to lic func tiun und higher initilll hClllllylllhin Ieve\:;. '11-.: la~t
observationmost likely reflects physician pr.actif,.'C to maintainhighe r h..11l11gluh inlevcl s in thuS\'
with symplo m:lticischemichean disease. Theindependentrisl; facto l':'l fnrde novoischemicheart
di"OCu<;e M:rc ul&:l' age. diahctcs.1he presenceof co ncentric hypcrtroflhy. LV dilatation Of systo lic
dysfunclion o n initial cc hocard iogram. as wellus h igh blood rn'SSu rc .low seru m albur nined lo w
calciumk:vcls avcrngcdow:r thc totllt imc Oll tlia lysis therapy. Thestudyalso ilIustmles that man y
nf the risk factors (age . diabetes. hyperte nsionand ccbocordlographtc abnonnalitics)for ischem ic
hcurt disease urccomrnonurthe general ami ESRD populatlons. 11 also suggests thatfactorsrelated
111 the uremic state. such liS hypocalcemia and hypoalbu minemia. may be lmportunt in the
p;lthngclIl-sis ufbchcmic I~ut d isease in ESHD.
~ Adv'll\ci ng age is associated withan increased risk o f eeranary ancrydise asein the general
ptlhlic (110.1 11).The vascular changes a ssociated nonnally ....ilh advancing age include atheroma
tkpnsil inn. increased intimal hcttmt;encit y 3Ild subendothel ial hardening(68.69). Age has bee n
a.o... ....\CiaI~'t! with oocrio gl'a(lhic coronaryart ery disease in the \,'CIlCrn1 ESRDpo pulation as II whole
115. 1121and in as)'mptomatK: diabeticpatients(113).
~ IllJ.....rte nsion is a well es tablished riskfactor for co ronary arte ry disease in thc
genera l Plflu lOllion ( I I "~ Hypert ension is very prevalent in ESR D rorulatiotl" (1 15 .116. 117)
l mody oanuc sludil'S haw shm 'lll ihat the sustained hypcn cnsiceor ESRD is due 10 c levmious of
J rip h...rulres istance( I IH). SUt;gesl~'tlIi1c lOrs leading to innppropriatcl)' high peripheral rcsisumcc
in l ~sltD include inahi lily Inexc retesalt andwa ter (119.120). ucrivauonof the renina ngiotens in
systc rn, increased production orthe vasoecnstrtctcr endothdin (121). lind activation of the
S~· Il\p:lthl.1ic nervous system(122.123). Th e rclalio nshipbetweenhypcnension andischemichea rt
diSl:asc inend -stage fen al disc~ has long beensuspected, though the amount or SUJIPOn inlldata is
",
sparse.In 3 rcno specuvc study of 310 patlcrushigh dias tolic blood pressure IcI'c1s .11 first dia lysis
were independently associated with s ubsequent ischemic heart disease while on renal n:pl ,lCl'lllC111
thcrnpy (124).
Di abetes McJ!jll15 Di abetes 1l1l::IIiIIiS is all inde pendent r is k factor for the dcvclupnu..m of cllwmlry
artery dise ase in the mm-ESRD population,altho ugh these nlsuputicurs hnvc an excess burdcu of
other risk factors. such as hypertension and dyslipoproteincmia (125.12(1). Our stud}' defined
ischemic heart disease on the basis of clinical S)'l11 ptOl11s. Such all uppronch nhuus t certain ly
underestima tes the degree of coronary artery disease in diabetic patients. in whorn there is a very
marked prevalence of ischemic hea rt disease . It has been estimated thai about II third n]"
asymptomati c diabe tic patients on renal replacement thcrupyhave 50%or more stenosis I II' lit l ea~t
one corona ry artery (127.12 8.129.[ 13), The prevalence of ischemic heart discase rises markedly
w ith age. For example Manske and en-workers found thnt RH% 111' usymptouunic t l iahc tk~
undergoing prc-tmnsplam sc reening coronary angiugmrhy had significan t arterial sle nll~ i s, In
pntlcnrsunder 4Sycn rsorngc. onlyparicrsswith each of the lililowing· diubctc s less thall S years.
nonnal ST segmen ts en arteri ography and a smoking hi story less than 5 p ack years- could he
predicted not to have ang iogmphic coronary artery d iseuse with any degree of cnnfldcnce
(sensitivity 97%und negative predictive uccurccy %% ) ( 113). These laucr studiesarc likely suhject
to selectio n bios: it is highly likely that the true prevalence of'usyrnpromarlc cunumry nrteryd i~casc
is much hi gher when thediabctic·ESRD population isconsidered in its entirety.
~ Smoking is upowerful risk fhctor for coronary uncry diseuse in the general pllflulation.
approximately doub ling the risk of car diovascular disease in the Frmninghum Study (I J (J), In the
lJSRUS Special Study of Case Mix Severity (N=3,399) smoking was associated with an excess
mortality 01'26%. even uflcrextensivecovariateadjustment. among incident hemodialysis patients
( IJI ). The independenteffect of smokingappears to beespeciallymarked in diabetics with ES RD.
in whom it more thandoubles mortality rates(132).
~ Increased low density lipoprotein (LOL). decreased high density lipoprotein (HOt),
a high ratio of total cholesterol to 1101. cholesterol and high Iipoprotein(a) levels nrc clearly
ussochucdwith coronary artery diseasein the generalpopulation (\ 32.133.134.135). It is less clear
whether high triglyceride levels nrc associated with coronary artery disease. Recent evidence
suggests that hypcrtriglyccridcrniamayhcu powerfulrisk factor when itcoincides with a high LUI.
hI 111)I. eholcslerol mtio(I J6).
ES]{D is ussochncd with quaruitative lipid disturbances. ll igh triglyceride levels and decreased
[lIll. levels arc typknl or both hemodialysis and peritoneal diulysls. while peritoneal dialysis
patientsmny a[sn have high LUI. levels (137.138). Several studies have shown that ESRD patients
tend 10 have higher lipoprotein Lp(a) levels than in the general population
(139,140,14I,142.I-H.144.l45). Qualitativeabnormalities arc also common in ESRD. Rcrnnnnr
particles llf chylomicrons lind very low density lipoproteins (VLDL) arc very atherogenic, as arc
oxidlzcd I.DI.. SOllie nf till: defects seen in ESRD patients include (a) ,I profound defect in
postprandial lipid disposal, which exposes the vasculumrc to high chylomicron remnant
concentrations (14Cl). (h) elevated intcnucdiatc density lipoprotein levels (147). (c) increased
heterogeneityof LDL and IIDL upuprotcins (147), (d) abnormalities of size and composition or
LDL and I-IDL panicles (147). (c) lncrcascdl.Dl . sllSl:~pl ih i lity IIIoxkkukm ( 1411 j n1Il1 rn 1I 11 ~n:d
cell su rface Lp t.cplropc rt:cogni t ion (149 ).
In general the design o f studies relating \lutC0111C to dysli pideniu in ESRD has been less than
optirnal. However recent reports haveassociateddysliphlcmiu \Iithcardiac dc' lth indi:,hctil ,.~', R I )
p.1ticnts( 150.151).lipo protcin(a) levels with cnrdiovusculur disease ( 152)ant.l vascular access lu s s
(153) in ESRDp;llients.
~ Other fac torssuggestedns risk (actors lbr vascular diseuse ill l ~SR[) patients includ e
chronic endothelial nc t ivrnion an d injury with ac tivation o f proth romh otic factors ( 154). high
homocysteine levels ( 155). high nhminnm levels (156) and defective clearance 0 1" advance d
glycosylntlon end-produ cts (157. 1511).
In our study hypocatcc min was slrongly related to horh de novo ami recurrent ischemic hea rt
disease. even after ndjusiing lo r age. d iabetes. blood pressure. hel1Hlglnhin und se veral other
possible eon fo nndiug vari ables. The effect \\~IS . IS marke d in peritoneal dia lysis patienls as ill
hemodialysis patients.•md could not he explained "way hy the dear «urccu rclalinnship bciwcc u
mean serumcalciumand time spent ond ialysis thcrupy.Anothc rgroup hasshown thatlowcalcium
levels arc independ ently associated with mortality in II very larg e cross -section or dialysis fllilie ll ts
(159.160). Hypoc alcemj u induces hypcrpa rnthyroidism. which may lead 10 pmfuund d isl urhm ll.;e.~
of myocar dial bioenergeticsand myoca rdial ischemia (16 1 ) Hyperpunnhyroidism has alS! l bee n
associatedwith dyslipldcmla(162 )and LV hypertrophy(163 ).
We observed a verystrong rela tionship between hypoalbum inemia an d ischemic heart dbc,l'{C in
this study, In the cohort w ithout ischemic disease a t baseline , lite ussncintion b nwccn
hypoalbunuucmia uud the subsequent oc currence or ischemic disease suggests that
hyponlbomincmiu is an important predisposing risk factor. llo w hypoalbuminemia could cause
ischemicheart d!:;casc is unclear. hut some possiblemechanisms aresuggested
(i) I ow ·,Ibumjn "'vel:; hw!lQjl h YPCTffijll'ub ble sl;)lc Inelderly, non-uremicpatients. malnutrition
isa.'tsocintetlwith heparin co-factor 11 and cmhhrominIIIdeficiency.whichattenuatesthe ability 10
inhibit thmmhingeneration (164). nis interestingthat low serum albumin levels were the single
factor mllst predictiveor access lhromoosis intheCanadianHemodialysis Morbidity Sludy.lcuding
10 spccnlntlon tlmt [ow orectic pressure associated with hypoalbuminemia lends to a
hypcrcocgulable snuc. as inthenephrotic syndrome (17).1 ow albumin levels n; llcct Olort: :sc\'Cn;
U[j'llljT nrcmh In! :; tn 'llhl'WI' l'D\'sis As discussed above. quantitative and qualitative lipid
nbnnrmulities <Ire cmnmon inESRD patients. and prohahly influence prognosis.The contributionof
nnlnutritiun and towse rum albumin levels to these nhncrrnalitics is unclear. In this study. the
inverse ns~;ocinl illn between serum albumin levelsand ischem ic heart diseusewas independent of
!lllal cholesterol levels. T he association between hypoalbuminemia and ischemic heart disease
elluld be a surmgnicmar ker lor a more severe uremicstare with endothelial cell activation. as
discussed above. Uremia m'll! its therapy may be a chronic.low-grade inflammatory stale. There is
aceull1\laling. cvidence rha r lntbunruation mayplaya major role inatheromaformation(165). It is
Ill' intcrcst thut Ilclicobactcr pylori. Chlamydia pneurnoulac and Cytomegalovirus infections have
IIl:CIl associated with an excess incidence of coronary artery disease in non-uremic patients
(166. t 67.IMI) . IIis well known thai lowserumalbumin lew is nlaybe a response lu inflammation,
independent o r protein intake. Whether such mechanisms may explain the recently reported
~ II
excessive mortality seenw ith pro-irulamrnatory. blo-incommtibl c hemOll iall'll i ~ membranes tlfm
is unknown.mi) I ow albu m in leye ls orc associ ated w ilh ,,!her O"!otipo ol "",kit- pries lIml I~
isch!·mie be·tO d jSC,1SC Recent evidence suggests tha t hypcrho mrcystci ncntiais l! risk n.ll'tllf for
athcrothrombotic cardiovascular d isease in l l~ gen er al (170 ) mill E SIW populatilllls (155),
Homocys teinelevels aremarkedlyelevated in chronic renal failure (171). In thegCllerall'lup ulilti!lll.
dietarydeficiencies ofpyrid oxine. fo licacid. pyridoxal 5'.phullphateand vitamin 1 ~ 1 2 nre th ought hI
bethe majordeterminants of' highplasmahomocysteine levels( 172),
PROGNOSIS. The natural history of ischem ic heart disease in ESlm patients has nnt hcen well
studied. In the USRDS Spe cial Stud y ofCusc Mix Severity.ischemic he art diseuse lit lusclinc was
Independentlyassociated w ith anexc essmortality 01"22%(131). In uretrospectivestudy, we llwnd
that both the presence and severity Ill' ischemic heart disease ill patients s tm1 i n~ maintenance
dialysis therapy were stro ngly as sociated with 6-month m ortality nncs (6) . In the current
prospective cohort study. pa tients were fbllowcd from ineep1ion uf l:SRlJ thcmny.hil t had tn have
survived for 6 months to be Included in the study. Aller lldj llst i ll~ for b aseline ageuud lliahcl :::
mellitus. patients with isch emic heart disease were 7{1"10 more likely to have an <Idmiss ilHl for
cardiac failure, 50% more likely to die. and 70% more likely IUhave a cardiac IIc:llh . Inilesc
patients most of the excess mortality associated with ischemic hearttJiseas..: nppcurcd III he vlafbc
dcvclopmcu of cardiacfailure.
CARIlII\C FAII.t JREIN[:NJ)·STI\GE RENAL DISEASE
])IACiN()SIS/\ N[ ) IIl JR I)f ~N OF D[SEASE. lngene ra l, cardiac results te rmsystolicdysfu nction
(I T di;lstuliedysfunction.Isc hemic heart diseas e canlead 10either functionalnbnorrnaltty; to further
cmuplicatc the situation, myocardial ischemia can al so be the result or systo lic or diast olic
dysfunction Cardiac failure is always a clin ical diagn osis: it occurs when cardiac function is
in;\\le4ui1te lilTnmlily reeds. There is 1\0 diagnostic te st lOTcard iac failu re. because it enn result
tftll\lseveraldifferentmechanisms.whichcan of tencoe xistinngjvcaindividual.
I'hccllntca1clli";.:m itl[ugy or cardiac IbilliTC in ES[tD is veryincomplete . The burd en or
t1iSC:ISl.l UppcllTS ttl be very high. In rolh our retros pective study (6) and the current cohort
pmspecttve study (15)clinic ully definedcard iac failure wasprese nt innpproxirnntcly ene third of
s ul~ i..cts . Appmxiuutlclyone quarter tlfra lients initially frccnf c nrdiuc la illirewe nt on10 ha ve nil
cpisntll.lIJrcartliac fhlfurc whflc ondia lysistherapy.
rUSK FA el 'ORS. To OUT knowledge. there has been no prosp ective study concerning th e risk
llleims rnrc<LRliac Iailurc in ESRDpatients. In thisstudy older age (baseline and de novo cardiac
!ililure). ischemic heart disea se (baseline and recurrent). diabe tes mellitus (base line). syst olic
dyslililctilll1 (llascii nc lind de ncvo], concentric LVhypertrophy(d e novo), LVdilatat ion(de no vo).
hypertension (tit: uu\"u). un cmia (de Al.JVo ). hypoalbuminemiu (tic no vo and recurrent ) and
hYI1(lCillcemiil (t1e nnvound recurrent) wereall indcpeud emlyasso ciatedwith cardiac failure . It was
impossible hi s,ay whether these risk factors arc connectedto cardiac fail urevia coronary artery
disease or \'ill myoc unlial ubnonnnlitiespcrsc .
PRO GNOSIS . 111C presenceof cn rdiac failure ,," <IS sll\l11gly. ,Iml ind o.: pcl\l.lcntly ilSSllC bl~\1 with
early demise. underscored by the ebscrvntionthnt 60%Ill' all IIl'nth s seen in lhis stud y IWn."
preceded by an episode of'cnrdinc fnilurc . Similar lindings have been reponed rclrllspcc tiwly h~
Hutc hinsonc t nl (173). a s wcllus pros pc ti vclvby the I ISRI)S (131).
"Ti lE FlnlJRE.
It is clear fllllll this study that many epidemiological qlM.:st ions 1K.'\.'lIanswers:
I. What is the target hl.'lTltlgluhin level for dialysis patients '!; will normalization (as COIllp.,n..'t110
po.ni'll clIH\.'\.1itln) .lnld iur.llc echocardiognaphic abeomulhics ?: if so. will this be translated inlOa
1\.'\IIK:liol1in cardiac mmhidity and mortality '!
2. Will lntcnsiflcntion nfdialysis deliveryhaw an impact (111cchocardiographlcand clinical cardiac
discus..:'!
J. Whill is the target blood pres sure level that minimizes cc hocardiographlc 3111.1 clinical cardiac
lliSl.':lsc'! Whatarc the most ;Ipprnpriu(c antihypertensive agents 10 achieve this? Is the inverse
rcl'lliulL'ihip between blood pressure and mort ality a marker for unw.'TIying cardiomyopahy unJIllr
Ilnig IIh.'rapy'! Hthc Inneris true. is ialn~\.'llic hypotensionpn.'tI isposingtu dClIth'!
4, Isthe ;L,sl.Ici;lliull betweenm;.lnulriliun;1111.1 cardcc diseasecausal. or dose it mark for some other
f ..:l' ....! Will inlensiliealiulltlfnulrilion.,1intake havean imp.'lCt on cebocardiographicand clinical
cantiaediSl.".Isc·!
~ , \\114lt is Ihe l:u-gel calcium levelfor dialysispali\.'flts? Docs hypocalcemia predispose to death via
hypcrpal'llhymidhilli. 111'via other mechanisms?
(I, \Vhilt is the rclarlonship IJcIWl,.'Cll torul lipid levels. lipid subfmctions and lipid turnover and
cartliac dis\.'ilSl.'in ESRD p.llienls '!
With th\.' l'ltls..iblc exception \I f #C!. these questions nrc probably best answered by means uf
r:UlI,lumi.l\."!Jcontrolled d ink ;llt ri;ds..n il..' lilllowing chapter focuseson the design of 2 clinical trials
which may help determ ine the optiruum hemoglobin und dialysis hucnsity lewis llcccssmy III trcu
the various manifcstatlcrts ef'cardiomyopmhy in chronic uremia.
ss
N<}RMAI,lZI\TION OF II EMOCiLOn rN LEV EL.
Question I is probably the most easily studied given the efflcncy of recombinant human
erythropoietin. A large muluccnrrcclinical trial is currently underwayin the United States to study
the impact or full normalization of hematocrit. in patients with symptomatic cardiac disease.
Mortality is the primary outcome lor this study, which is being sponsored by the Amgcn
Corponuion. Secondary end-points include the changes seen in len ventricular moss index. Data
from our cohort study have been used in the trial design.
The ltllluwillg Cunadiun muhiccrure tria l is proposed .
OBJECTIVES. The primary objective of fhc study is 10 :lSSCSS the effect of hemoglobin
1\1Irnwl i"ntiol1com pared 10 part ial correction of'nncmla. using cpoctin ulfa in hemod ialys is without
symptouurtic cnrdlac disease who have either ron ventricular hypertrophy or len ventricular
~'ilaln lilln lll1 ...chocunliogruphy.
RATIONALE. Anemia is an independent risk factor for LV dilaunlon end concentric hypertrophy
in ESRD patlcnts.ns shownin this and other studies .
DES!ON. This is un opcn lubcl study to assess the effect of two target hemoglobin levels. 100 gIl
and 135 gil Ull canljumyoputhy. Patientswillbestratifiedaccordingto whether or 110t they have lell
ventriculardilatation. Esscntlnlly. there are two studies : ( I) to assess the exte nt of regression of LV
mass in patients whh concentric LV hypertrophy and (2) to assess the extent of regress ion o f LV
cavity volumein patients with LV dilatation.
l'A I'lENlS. Pulienls ellleringthe study must fulfil the followingprincipal criteria:
LAgc > 18 years.
2. On hemodialysis > 3 months.
3. No myocardial infarction, admission lor angina or cardiac failurewithin the la:>1 I~ months .
4. On cpoctln alfa>3 months. with hemoglobinhcIWeel1 l' 5g11mil Hl5gil in the previous month.
5. Stable vascular access lor the last 3 months.
6. Life expectancy > IHmonths.
INTERVENT[ON. Patients will be randomly assigned 111 either the high ([30. 1-11 1WI) or normal
(95 - 105 gIl) hemoglobin target group. Patients ill the high largel gl"\lllP will have their
hemo globin s ramped upward s using <I pre-sci cpoctin dosing schedule. the r:lmpin!;! will lake place
over a six mo nths period.
OUTCOMES. Echocardiography will be performed at baseline. 12 mouths and lit IKlIlonths. The
change in mass index (component I above ) or cavity volume (cuutponent 2 "huve) at 12 months
willhe the primaryoutcome.
Secondary outcomes will include the change in LV parameters ut Ill lllotllhs. morbidity. menulity,
safety. quality ofli fcami phnnnacocconomiceffects.
SAMPLE SIZE CALCULATIONS.
Study I: Assuming a = O.OS (2-tailedJ. b = 0.80 and tha t the standard deviation otrhc c111111gC in
mass index at I year is 37 glm~ (as was seen in this study), the number orparlcnts needed tn detect
"(127 g1m2 difference betweenthe low and high hemog lobin groups is ] O~r treatment an n (I N ).
Assuming 11dropoutnuc of'J2.5%. 35 subjectsper patientann nrcrequired.
Study 2: Assum ing a = O.llS (2·taikd). h = lJ.KO nnd thai the standarddeviation of the change in
cuvity VUIUlH: ill I year is 3 [ ml/ni (as was SL'CII in this study), the number of patien ts needed 10
dctcct u 24 ml!nl difference between the low and high hemoglobingrou ps is 27 per treatment ann
(174). Assuming u dmp out rateof 12.5%. 35 subjects perpatient armarc required,
ANALYSIS, The intention to treat principlewillhe used primarily. where patients will beanalyzed
accord ing til the gmup they were randomize d 10. regardless of whether or not they achie ved the
hClllllgllihin level. Pure efficacy analyses will also be performed where only patients who reached
their largct hemoglobin willheassessed .
Thechange in muss index (study I ) undcavity volume (study 2) in the two ucarmcnr groups will be
compared using II pnrurnctric test. Multivariate analysis of variance may he lI S~,{[ should any
imlmluuccsbetween patient groups occur during the study. in terms of blood pressure levels or
dialys is intensit y.
INTENSIFIEDDIALYSISn IER,WV
OBJECTIVES: To IL'SI. the hYPOIIK.-sis 111:11 inct\.':1.",-'I.I amounts Ilr dialysiswill imprun: diminishc'\!
contractilityin patients with end-sage renaldiseuse.
DESIGN.This is a ruulticentrc. cross Call3da.rnndomiscd. oren-label. l'\1ll1mlk\1clinicnl mnl. 711
chronic hemodialysis patients wilh L'ChOLw.mlillgmphic systolic dyslunctiou Ifr.tclilll1al sllllrt l.'n i ll~
less than or equal 10 30%) will he randomly nssigncd ro receive either st.mdaru dialysis intclIsitr
(KTN 1.2 -rnngc l . l to IJ inclusive)or hucusiticdthcrapy (KTIV lJl -rnngc l oS 10 1.7 ind usiwl
lor a total of \S months. 3 months will be used III ramp dialysis inlcns;ty III IIIL' larget range:
p uticrns will he maintained .u la~L1 I1l1lgC for a further I:! Illonths. Edu"IC:m.l illJ,!l1lphy wilt Ill'
repeated at6 and 12 months o f the maintenance period.
PA n ENTS. All patients with the followingcharacteristicsarcdigihle:
I. On hemodialysis lhemp)' for mJeast 3 mo ruhs.
2. Stable arteriovenous access.
3. Predicted survival > I year.
4. Technicallysatisfactorycchocardiogrumwithin 6 months uf'nnulomi.....uion.
S. No myocardial infarction or unsteblclITI!!inll within the rrevillus year.
6. Absence otC lass IV NIlIAU cungestive heart fuilure.
7, Not pregnant or judged capableof bccoming pn.t; nalll.
"INTERVENTION. Random a...signmcnt 10either standard KTN (1.2) or intensified KTN 0 .6).
f}iaJr- is wi ll he intensifiedby iocrcasinglimeon dialysis. and by increasingthe performance ofthc
('li.lticnl..d ialyh.'f l1l,."fIlhrnfll!.
( IIn U> ME. "11K:primaryoutcome measurewill be the change in li'octional shortening between the
O;,l"Clinc ccbo. and that performedat 12 months into the study.
Sccnl1(~IrY outcomes will be ( i) lhe change in fractional shortening.between the baseline echo. and
tlnuperformed at 6 months Into the study, (ii ) lime 10 death or congestive heart l:1 iluTC.
SAMI'I.E SiZE. 7Mpatients inour prospectiv e study had tractional shortening less titan or equal to
J()"/_ ti ll initial cchoc ardiogrophy. and had a second echo ooc year later. The fall in fmctinnal
shortening wn..4.2%. witha stcrdo rd deviation o f7.3% . To det ect a cbangc of5%. with a 2·uilcd a
ti l' lUIS lIrnJ a b (If 0 . 1. the req uired sample si.. c is 28 s ubjects per group. Ass um ing a 25% loss to
ftllluw- up (til dea th or change in mode of ESRD thcr.Jpy)during the IS mon ths o f the study the
requiredsample size is JS per treatmen t ann .
AN AI.YS IS. 'Ilk: inten tion to treat rrindpJcwill he used primarily. where patientswill be illkllyn:d
lIcctlnling.lt1Ihe gnlUp the)' W"'1'\.' randomized to. regardless of whether or not they achieved the
hl.'lllugl\lhin leve l. Pure Cm Ca C)' analyses will else be per for med where only patients who reachc-J
theirlilrgC:1KTN willheassessed.
The dmnge in Imctionnlshortening.in the two treatment groups will be compared using n
p arametric test. Muhivanatc nnalysis of variance may he used should any imbalances between
plltil.'nt gn1uJlS be prcscm ut b aselineor occur during the study. in terms of hemoglobin or blood
~s.""lrc ll:\·ds.
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lJ illhele.~llld l i lus ( 'Yo,)
( 'uwllary at1eryuisellsc/ % j
Anginapectoris(%,j
( 'lll'diae! ;lilurc( 'Yo,)
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Table 2. Echocnrdiogruphicand Clinical Outcomes.
OUTCOME
Diagnosis 0 11 follow-up cchucanliogruphy:
Normal
Concentric len ventricular hypertrophy





















(l7/432 ( 16% J
70/432 ( ll,'%J
uTable J . I'mgnusis. Adjust!.'" Relative Risk nf Ovcrall MOr1011ityami tate Mortality (> 2 YI."ilI1i).
U:l~i c Model CJ\\.'f"dIlMurtaliIY Late Mortalit y
1Il >C:llhsllf AI 145/4211 70/2IXI
(i s!.;
RR RR
Age /years ) l .fI] 1 < In-I 1.035 O,llOO9
lIinbctcs mcllitus 1.952 O.lHlO2 1.915 0.009
( 'nr mlcry dis 1.1122 O,IHI 1.156 0.697
AllJ:!. inOl l'ccluris I.:WI ll..fIJl) I.OJ4 0.923
( ':mJ i:lClililll R: IJW(, 11.11006 1.790 0.0 15
Alhum in lgldl J 1I.7oJ4 (J.079 0.674 0.046
t "u\'an alcs adlk.J'
Alri:11 IAU.l n.)') 1 1.390 0.353
dp;r hylluuia
I'VI> I X !; 0.11 14 2.71K 0.004
t.cn W lllricll lllr:
tvlilSS( ~/Ill~) l. tHl] 0.107 1.009 0.0007
Hypertrophy 1I.HS] 0.555 1.779 0.214
Villumc( ml/nh 1.(I(1l) 0.011 1.011 < IO-l











u. Ad,justcu fer age. diabetes. coronary arte ry disease . ;Illgina pl'ctoris. cardiac failure.
ulbumin.
h. Added oneat a time10NISi!.: mudd .
"Fable 4. l'atic uts WithnUI Systol ic Dyxfunctirm. l'rugnos rlc lrnportu ncc of Len Ventricular
Parameters. Eslin1<llcd Separately Fur All Subjec ts (N=343). ']110sC With Normal Cavity Volume




























Volume ( 11l 1/1Il~1 NA
MassIVtl1tl!!ml) 1,41K
I.V D1l.ATA Ilt );-.:
RR~ lm h
Muss NA NA NA NA
i lldcx (i¥m~ )
Volume (ml/m~ l 1.0 10 11.0l1ll 1.01K II.tKIl
MassIVol (g/mll NA NA IJ.l K~ (W I"
it. I V. RR and Nit. d.....llllc - Iclt venncutar". " relative risk" :m.1 -1111(:1S....ld. II....l".
h. Adjust...-d for hasd incage. d ial1l:Ics and ischemicbean disci,s.:.
!7
Table5. Impact of EcJMlCarJio!!mphie Classification UI1 On..'m.1IMortality and Late Mortality in
Expundcd Mu ltivariat e Models .
<)VEI{,o\I,1.
M( JRlAI .lTY
Sh:p VariLhlc I k~
Canli,ll;l:lilurc 21),1















2.19 « Wil l
1.52 (U162
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<I. Till: variables included in each t' 11:-;'S Ikgrcssinn lllkilys is were I.V g~·tll1lc l ry, ugc. ~~· l1I h: r.
baseline serum albumin and lK't1\Oi;lobin levels.
b. Entered as I: Normal LV volume, m lL'i.-l ( 120 wm~; 2: LV J ilalalillll. U lh lll lC ( 1 2111111/m~ : J:
Normal LVvolume. mass > 120 g11ll~: 4: I.V dilal:lliun. volume> 12lJ11l 1/1ll~ .
The relative risk is lhal associated with a clumgc Ill' 1 srnuum. Therelative risk Ilf dcalh lill"llilliclll
in stratum 4 wn uld be I.soz', 'If 5.ltS times tiuuuf un omcrwisc cumpilrahlc Ilill i ~'11 1 ill srr auuu I.
Table rl, I'Rlgllusti l: ImpiK:t of Proposed Ct assificnicn SY1lo1CUI (II ) Compared to the Classification
System or Kuren ct aI7.(I),ln Patients Fre uf'Symptomatic Ilea" Diseaseat Basclire"
SYSTEM J SYSTEM II
EVENT Rltd ItR~
I)cHlh 1,00 O.9K 1.51 0.1129
1 ~ l l c dcmh 1.15 11.4 2,JJ O.lM}J
Ml lll'llngiml 1,62 O,CJ6 un 0.044
L'nrdinc fuilure 1,111( 0.56 1.50 0.015
a. It lt denotes relative risk, MI myllcanlial infarction.
h. Elilcn.,j ao,; I: LV I1I:L...o,; S 125 Wm~. rclauvc wall thickness S 0.45; 2: I.V mass sI 25 Wm2.
relative walll hicklll."S..o,; > 0.45; 3: LV mass> 125Wm2. relativewallthickness s:0.45; LV mass >
125 l;Im2, rclatiw wall thickness > 11.45. Therctativ·c risk is that as.sociatcd wi th a change of 1
C, lnrcrcd ns I: Nllml:ll l.V volume. mass S 120 tynl ; 2: l.V dilatation. volume '$ 120 ml/m!; 3:
Normult.v volumc.umss > 12UWlIl~: 4: LV dilatation. volume > 120 11I1/111~.
l' hcrchuivc risk is rh.u associmcJ with a change of I stratum.
II, A\ljll.'ilL'tl lilr hasd inc agc and dillhclCS lllcllitlls.
Table 7. Assoctmicnst of'(lj ConccrnricLV Hypertrophy (LV MassIndex'> 11tl 1:!"1Il!,
Cavity vclumc s 90 mllm2, FractionalShortening> 25'%)( 11)I.V Dilauuicu(l 'll\'il~'
Volume> 90 mllml , FractionalShortening> 25%), and (III) Systulic Dysfunction
(Fractional Shortening J.: 25%) Using PaticrnsWith Normal LV us Reference l 'ah:l,luryl,.
ABNORMALITY ASSOCIATIONS OR
Couccntric Lv l l Age (years) I .ll) < !l.ot )]
Male gender 2.23 0.1162
Dinbetcs rncilitus 2.40 0.1)27
Coronary urtc ry 2.65 0.071
diseuse
Hypertension > I()yrs 2.25 O.lJ.lJ
llellltlglubin O,9K 0 .032
LV Dilatation Age (years) 1.03 0.l 1l0
Male gender 4.52 ". CUIIl I
llcrno globln Ig/l ) 0,96 ,' tl,(IOI




AIlNC)J{MAIJ TY ASSOCIATIONS OR
Sy.~ttJ l i c dysfunction Agc( ycars) 1.{I6 < 0.001
Female gender 4.45 0.003
Coronary artery 7.25 0.007
disease
Alhumin (!:!/!) 0.93 0.05
a, The eovnriatcs included in cnch analysis were age. gender. dia betes mellit us. coronary artery
disease. lmgina pectoris. hypertension > 10 YCllTS. arterial pulse pressure. mean arterial blood
prcsssure. hemoglobin. bleed urea. serum creatinine. inorganic phosphate. calcium • alkaline
phosphamsc lindserum albumin levels.The global p-valuc was < 0.00I lor cnchanalysis,
h. LV denoles "11,.'11 ventricular". OR "odds nuio" ,
Table 8. Patient Characteristics. All Patients (Group I. N '" 4.l2) antl l'atRmt
SU~'1 with Repeat Echocanliogrnmll(Group 11.N::::!78t .
IMSELINE DATA GROllI'I UIWIII'1l
AllC (YL"ars) 51. 5·H
Mah:lFcmalc(%) 64 /36 (1.'1:17
Renal disease (%):
Glomerulonephritis 31 3(1
Diabetic nephropathy 20 1K
Tubulointcrstitial I I 12
Genetic
Ncpbrosclcrosls
Other IK I ')
Unknown
Hypertension > 10 yea rs (% ) 29 J2
Ischemic heart disease (%) 22 25
ClInliacfll ilurc (%) 31 33
SERIAL DATA
Mean arterial BP(m m Ilg) 101* II 1IlI :l.:II
Serum albumin (gil) 37 *5 37 ± ±
Hemoglobin (w'\) 89 . 9(J ·l
Tublc x. continucd.
1I. Cunlintluus vnrlublcs urcexpressedas mean plus or minus standard deviation.
There were lUIstatisticallysignificant differences betweenGroup I andGroupJ1.
Tablet). EchocardiographieDiagnosis \\ll Uasclinc and Follow-up FchIlCilnliugr.lr!IY.
Pc..formed At A Median Intl,."T\'U1 of 13 munth.~a.
2l1li[('110
\01 ECII() Normal Corccuri c LV Sy's!\·lic TIHAI.
LVII Dilatation l)ysfn"'liull





LV zo 29 I' (1)
Dilatation
Systolic II 2S .7
Ilysful1Clio
TOTAL .13 t)l) ... .', 2-lS
3. LVdenotes ""len ventricle", LVII"lcn ventricularhypcrt"II,lly- .
Tab le 10. Assoc iatio ns of The Presence of Concentr ic LV IIYJX.'11rophya mul I.V M,lSS 111llcxb in
Patients With Co ncentr ic LV Hypertrophy (N-=IO:!) or Nomuu LV (N"'J5) lin Follow-U p
Echocardiogmpby".
OUTCOME ASSOC iAT IONS OR
Concentri c SystolicBP [nun I-Ig) 1.03 n.u:!
l.vhypcrtropby
Femalegender 2.6 lUI]
LV Il K1SS index (gll1l~) Systolic BI' (1IlI11 I Ig) +O.9:! oeu
Agc(ycars ) + C1.57 0.1105
ll cmoglobin(gfl) · O.S:! 0.1105
a. Usi ng multiplc logistic regress ion.
b. Using multiple linear regressio n.
c . The covariatc s used in each model wcre ugc, gender. diabe tes mellitus . ischemic heart disease
and mean hemoglobin. systolic blood pressure. serum albumin und calc ium levels up to the thc
secondcchocardiogram.
TnblcI I, Assocknicns of The Prcscnccort .v Dilatation" and LV Cavity VOllJnChin Patients With
I,VIJilalntilln(N"'65) or Normal LV (N=J5)on Follow-UpEehocnrdiography'
(JlJTCC)MI ~ ASSOCiATIONS OR
t.vdilarauon lschcmic hcnrtdiscasc 5.1 O.OOS
HcmoglobinIg/l} 0.96 0.02
DiastolicI3P 1.04 0.06
('lIvity vnlulIIc(m l/m1) tschcmicbcan discasc +24. 1 0.009
Hemoglobin (gil) ·0.45 0.004
Diastolic131'(111111 fIg) + 0.8 0.04
Serumnlbumin (g!l) -0 .85 IUJ4
a.l J sill!! n ll1 lliplc ln~isti c regrcssi nll .
b. Usingmultiplcl incar rcgrcssion.
c. 'J1w covariajcs used in each model were age. gender. dinbercsmellitus. ischemic hcan clise asc
and mean hemoglobin. diastolic blood pressure. serum albumin and calcium levels up to the the
seCllul,.:ch tK:mdiogrmll.
Table 12, Associations of The Presence IlfSrstnlic Dyslimclilln" :U1l1 Fractional S l lllrll'n i l1b\~ in
Pntlcnts With Systolic Dysfunction (N=57) or Nonual LV tNo:.35) 1111 Flll\llw-Up
Echocardiography".
OUTCOME ASOCIATIQNS OR
Systolicdysfunction Ischemic heartdiseuse 5.2 IUlIl I
Fractional Ischemic heartdiseuse -6 ..1 lUI:!
Shortcninb\(%)
llcmoglobin tg/l) n. ln IlJl2
3 . Using multiple logistic regression,
b. Using multiple linear regression.
e. The covariatcs used in each model were age. gender. diabetes mellitus. ischemic heart disease
nnd mean hemoglobin. diastolic blood pressure,serum albumin and calcium levels up tu the the
second cchccardiogmm.
l ank 13. TheImpact of Renal Transp lautntion : Patient Characte ristics (N== I02)",
Agc (year.~)
M"lcJlcmalc ('%)




( 'arua c lililufC(%)
! lyrc rtcnsioll (% )













t1. J: refers In meanplusOf minus struulnrd deviation.
Table '4 . The Impact of'Rcml TransptantationonEchuc:m.lillgmphk 1' :Ir. llI k 1l 'n' IN '~1U11·.
PRE !'OST
LV mass index (giro ! ) 175%62 I ·U~± 4J -: RUol
LV h)·ertrophy 10/_) R(, 71 < 1I.tKII
Cavity volume (mllnl) 86 ± 35 74 ±:!.5 ·; II.lMll
LV dilatation (%) 4) 29 < 1I.Oll1
Fractional 35 ± 9 37 ± 7 0.11)(,
Shortening( % )
Diagnosis (%1
Normal reference 10 25
category
CoocmricLVII 44 46 tWI'!
Lv dilatation )4 )0 tl.UJ
Systolicdysfunction 12 If O.lllM MlX
a. ± refersto mean plus or minus standarddeviation. LVdCIMlles IcI\ ventricle. I.VII h:1lventricular
hypertrophy.
b. Total exceeds IOO%Juc to rounding error.
10:-
'lublc 15. Echoc:mJingrJphic Diagnosis Prelind Post Transplantation".
POST
PRE Normal Concentric I.V Systolic TUfAI.
l.VII Dila tation Dysfuction
Norm al 10
Concentric III '7 43
I .VI I





Te TA!. :!5 ., ::!l)
"'
a. I.Vdcnotcs "ld ) ventricle", LVI[ "Ieli ventricularhypertrophy".
Table 16. The Prognostic Impact of Baselinelsclu-mic 1leon Disease",
lUI
OUTCOME

















u. OR. RR. and NAdenote"odds ratio". "rclanc risk" and "nut ussocintcd".
b. Using multiple logisticregression,
c. UsingCox's regrcsssion.
d. Adjus ted for baseline age and diabetes mellitus .
102
T:ll1 lc 17, Assuci atiuns~ oflschcmic Heart Disease at Bascline h•
LV dillltlitioll NA



















Curren t smok ing
AS~;( )(,IA' I 'I( )N
/\I,!cfycar:»
Dinhctesmclitus
ll ypcrt cusinn > 10 yeurs
Sc rul1lehn[cst eml (mllmll l)
IIC11IOl,! luhill( 1V11
Scnnu ulhumin(1V11
l ~chtJcarJ iugraph ic diagnosis :
Nonnnltrcf crcncc cntcgory)
Concentric I.V hypertrophy NA
a. t l si ll~ multiplc lu~ ist i c regrcsslou.
h. I.V. (m and NA denote"le tt vcutr icuhu" . "odds ratto''and "not associated".
c. Au.i",stcd /ilr ugc.diabetes mellitus. hypertension > 10years. smoking and cholesterollevels,






Scrum cholcac rol tmmcld) NA
Cu rrent smoke r NA
Echocardiographicdiagnosis:
Normaltrcfcrcncc catcg ory j
Corccmric LV hypertrophy 5.CJ2
Lv dil atation 5.35
Systolicdysfunction 12.1
SERIAL'
Hem oglbln (gil) NA
Diastolic DP (mm Ilg) 1.04











a. Using Cox's regression.
b. LV. RRand NA denote "left ventricular". "relative risk" and "nut assochucd''.
c. Averaged from the start ofdial)'sis therapy umllthc devclupmeni llfi sc.:hcmic heart disease.
Table IS. continued.
d. Adjusted filr baseline ugc. diabetes. cholesterol. and smo king and serial diasto lic bloodpressure
Icvd s whilc on uialysili lhcrJ.I'Y·
Table 19. Associations"of'BaselineCanliac Failurl .
ASSOCIA'n ON Adjm;tl.'\l~ OR
Age (years) I.'" <uun
Diebctcs mellitus 1.71 ' : II.{IIII
Ischemic he art disease 3.17 « 1.(1111
Ilcmoglobin (gIl) NA NA
Scnnu albuminfg/l) Ni\ NA
Echocnrdiogruphic diagnosis:
Normal (reference category)
Concentric LVhypertrophy NA NA
Lv dilata ticn 3.32 lUl lS
Systolic dysfunction 13.3 .-:11.1 1111
3 . Using multiple logistic rcgn:ssion.
b. LV. RRand NA denote"len ventricular", "relative risk" and "nlll a.·i.''llCi'IIl'tl''.
c. Adjusted for age, diabetes. ischemic heart diseaseandhypertension > f(J years.
1O~
'00
l'ahle 211, l\ ssnciations' or ne Novo Cardiac failurc~.
i\ SS I)C 1AT IONS Adjustcud RR
l iASI ~ I.lN E
Age (years) 1.02 0.044
Ij iabc tcs rncllitus NA NA
Ischemic heart disease NA NA
Ikhncard iogmphic diagnusis;
Normal (reference category)
Concentric LV hypertrophy 3.5K 0.002
I,Vlli hllalioli 2.97 0.019
Sys hllicdyslimctiull 3.40 0.032
SERIAL
Mcnunrtcriul Bl'{rnm l lg) 1.03 0.026
Ilcm ogl\lhin (g/l) 0 .96 <0 .001
Serum nlburnin (,yl) 0,93 < 0.001
a. UslngCux's rcgrcssion.
h. I.V, RRmillNA denote "lcfl ventricular". "relative risk" and "notassociated",
c. Averaged fromthestart of'dialysistherapy untilthe development of'cardiac failure.
d. ,\\!iUstl't.l for baseline ugc. diabetes. ischemic heart disease and serial mean arterial blood
pressure levels while on dialysis therapy.
Table 21. Associations" of'Recurrcn t Cardiac Failurch.
ASSOCIATIONS Atljtt"II..~ RR
BASELINE
Age (year.;) NA NA
Diabetes mellitus NA NA
lschcmic hccrt discasc 2.03 nJKI3
Echoc crdio graphlc diagnosi s:
Nonnal (reference category)
Concentric LV hypertrophy NA NA
Lv dila tcuon NA NA
Systolic dysfunction NA NA
SERI/\L
Mean arterial OP (rom Ilg) NA NA
Ilcmoglobin(g/ I) 0.98 (W I}
Serum albumin (gil) 0.95 lJ.l)(w
a. Using Cox's regression.
b. LV. RR and NA denote "Iell ventricular", "relative risk" lind "nllt associated".
c. Averaged fromthe stan of dialysis therapy until the development of'curdiuc failure.
d. Adj ustc<.l for baseline age. diabetes. ischemic heartdiseaseand serial mean arterial blood
pressure levels while ondialysis thempy.
1Il7
Table22. PatientCha racteristics According10 'Fertile nfMc.mllemoglohin Level",
BASELINE > 1J5g/l KO-(){)gil S 80 gl1
Agcfye"fS) 52 ± 16 5] ± 15 49 ;1:: IN O,OS
M/F 66%] 4% 64%/35% 640/0/37% 0.9)
Diabetic 32% 28% 31% 0.Q3
Renaldisease :
ON 32% 29% 31%
lJiuhclk 26% 19% 14%
Tubulolntcrstitinl N% 12% 11%
Genetic 9% ] % R%
Nepllrtlsclcnlsis 9' l!o 7% 7%
()Ihcr 11% 22% 20%
lJnkl1lm'l1 4% R% 8% 0.07
B1' > J(J years 19% 23% 36% 0,005
lschcr ntchcnrt dis 34% 21% 12'10 0,0000 1
Curdiac fuilurc JS % 35% 21'10 0,004
SERIAL
~ 1 t\ 1 ' ( 1ll 111 1 I g) 102 ± ]() 100 ± 12 101± I I O,2~
i\ lh\llllill (g/l) J7 ±4 J7± 5 37± 11 OJI
<I, Cuutinuous data nrc expressed as mean plus or minus standarddciarion
Table 73. Independent Impact of Anemia (Expressed as the Effect of A Full in Mcnullcmog luhin
Level of 10 gil) on Echocurdiogrnphic and Clinical Outcomes in The Combined Group of
Hemodialysisand PeritonealDialysisPatientsandHemodialysis Pntlcnts Onlra.
OUTCOME IlDund PI) Ill>
Adjustl-dhOR(p) AdjllstedhOR (pl
Normal(reference category )
LV dilatation NA 1.49 (1I.11W)
Systolicdysfunction 1.42 (O,OlK) 1.55 (lUl4K)
Adjustcd '' OR(p) Adj usll'tlh()R(p)
Cardiac failure:
De novo 1.28 (0.017) 1.24 (u.n2K)




DeaU1 1.14 (0.024) 1.25 (1l.U37)
a. HD denotes hemodialysis. I'D peritoneal dialysis. OR mitis I<ltiu. RR rchaivc risk, uml NA IIlI
statistical association . b. Adjusted for age. diabetes, ischemic heart diseuse (excluded lilr the
outcomes de novo and recurrent ischemic heart disease) anti the average monthly mean arterial
bloodpressure.serumalbuminand hemoglobinlevel beforethe index event.
110
'lublc 24. EdlOca rdillgraphic and Clinical Outcome According 10 Tcrtifc of Mean Hemo globin
Level, mrhc Combined Groupof Ilcmcdialysisnnd Peritoneal Dialysis Patients".
()l JTCOME
Concentric t.v hypertrophy:
> 95 g1J(rcfcrcncc cu(cgory)
xu ~ 95 gil
£IWg/l
Lv dilatatlou:

























80 . 95 g11
£8 0g /l
Death:
> 95 g/I (referencecategory)






a. OR. RRand NA denote odds ratio. relativeriskand no statisticalassociation.The
b. Adjusted lor age. diabetes. ischemicheart disease and tile uverngenuuuhlymean llrteri<l l hllllll.l
rrcssure,scnJmulbutilinundhc1l1oglobinlcvcl before theindexevent .
Ta ble 25. l' a ticnt Chumctcristic s Accord ing 10'Fertile ufM can Arteria ! B1uml
I I J\SEI JN I ~ ~9N mm l lg 91\· 106mml lg > 101"! 11lm llg
A ge (ycars) 56 ± [ (I 59± 17 4R:l:: 16 0.002
MIll f!l o/,./39",{, 62%13 1\0/", 71%12% 0.13
Diubc tic 33% 23% 21% 0.10
riP > Iu ycer s 37% 49% 19% 0.007
lsch crnlchcnrt dis 33% 2 [% 13% 0.0005
Ca rdiac fail ure 40% 30% 23% (l.OO6
SERIAL
llcrnoglobiu (gil) IP ± 14 89 ± 15 &9 ± I f! OAI"!
AlhulI1 ill(g/I) 36 ± 5 37±5 3 8 ± 4 0.03
:I . t 'ontinuous dil l;l nrc ex pressed as mean plusor minusstandard dciution
I I :!
Tobie 26. Echocardlographic and Clinical Outcomes: AssociatedMean Arterial Blood
Pressure Levels ,
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OUTCOME ffEVENTS/#AT RiSK MAl' (nunllg]
Concentric LVl-I 102/159 (391110)
LV dilatation 65/259 (:!5%)













No 227/299 (76%) 10l ± II
Yes 72/299 (24%) 104 ;1:;1)
Recurrent
No 62/133 (47%) [0 1 :1: 9
Yes 711133 (53%) rur, 12
Death after
admission
No 47/133 (35%) 104 ± 11




TahIo.:2(1.~ 1Il I i nlJ..'d .
OUT COME IIEVENTSI'A T RISK M AI' {mm JI~)
bc:hc ll1ichc:lrt tliSl.':l.'iC
1~11C1"'
No 297/337 ( 8&%) 103± II
Yes 401J37 ( 12%) 103 ± II 0.5 8
Recurrent
N" 41)/1)5 ( 52%) 98 :1: 10
Yes 4MlJS (4 8'4) 101 ± 1O 0.18
llcath lln~r
:I1..hn i!;.\iul1
N" 23m () 2%1 101± IU
Yr.-os 5Um (68 %) 95 ± 13 0. 10
Ib lh
N" 282/432 (65%) 103± 10
Yes 15{1/4J2 (3W,) 98 ±1l < 0.0001
Table: 2 7. Indc:pc:ndc:nl Associmioo Between Bloodrn.-s.'lUI\' (t1l1:EITt,'ct tit"1\ Rise in ~ I~~m l\ n \.Ti:1I
Blood P ressure Level of 10 mm I llll and r:.clu.lCanJio~r.l~h: and Clinic:ll Ouh:nnll.'l' in Ihc
Combine d Group o f'Hcmediulyslsnnd P~'l'itoncill Dialy~i!l l 'alic l\I~".
O UTCOME ALlj ll!ltl.'d~OR (p1
Nemnl ( reference category]
Ccecntric LV hypcrtropby IAR (IUI2(11
LVdilnlat ioo 1.4R (lI ,lIiH)
Systolic dysfunction NA
Changei n LV: hlP)
Mas.~ i nde:t(ll/m2) +5.4 (1I.H27)









Dath O,X2 (O.lX, ))
Tah le 27. con tinued.
:I , <m.denoles oddsratio. RR relative risk. and NAnosmtisticalnssociutinn.
h. Adjusted for ugc.diubctcs. ischemic heartdisease (e....eluded for the outcomesde novo and
recurren t ischemic heart d isease) a nd the average monthly mean m1eri"l blood pressure . serum
ulbuminnnd hemoglobin level be fore the index even t.
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Table 28.1ndcpcndclll Association Betwen Blood Pressure( the Ell'ccl ofA Rise in Mcuu Arterial
Blood Pressure Level o f 10 mm l lg j Oil Ech ocaroiogrn phic and Clinical OUlcomes All:1ly,._c~1
Separa telyin Hemodialysis and PeritonealDialysis " "lienls".
OUTC OMl! HEMODIALYSIS PERITON EA L DII\I.YSIS
Adjus(cd"OR(p) Adj usll\lhO I{ (p)
Normal (reference category)
Conce n tric LV hypertroph y NA 2.16 jlf.{lIX)
Lv dilatation NA NA
Systolic dysfuncthm NA N!\
h lp) hl p}
Change ill LV :
Muss illdcx(g/m2) +7.2 (O.0411)NA NA
Cavity volum e (1111/1112) NA NA






















:l. 111> dcoorcs h~·Il I\ld ialys js. 1'1>peritone a l dialysis. ORodds nuio. RH relat ive risk.•md Ni\ no
st:l1is llcal:lsS<H:ialiun.
h. Adjusted fo r agc. diabetes. ischemic heart disease (excluded lo r the outcome s de novo and
recurrent ischemic heart disease) und the average month ly IllC'JIl arterial blood pressure. serum
nlhurninnndhCllluglllbin level beforeihc i ndexevent.
l1'l
Table19. Patient CtsmctcrlsrlcsAccording to Tcnilc of'McunSerumAlbumin Lcvcl'',
BASELINE $ 36 gil 36 - 3llWi > J1lglI
Agc(yrs) 54 :1:: 16 53 ± 16 ·Hdlc. {l.OOO2
Malc/Fc nmle 59%/4 1% (,90/013 1% MI%In% o.tn
Diabetic 34% 27% 14% O.lHMl5
Hypertension 3lJ% 31% 26% 0 .(,"\
> Iuycnrs
Ischemic 26% 25% 1J% (UI:!
heartdisease
Curdiuc failure 34% 35'% 22'11" lUll,
SERIAL
Hemoglobin (g/) 88:1: 17 8K± 14 RIJ± 15 O.tJl
MAl' (mm Ilg) 100:1: I I 101 :I::II 102 ± 10 O. l l)
:I. Continuousvar iablesnrc expressed asmea n plusor minusstandanldeviation.
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'Iublc 30 . Assud util1o ll!: tWl.'l:11 Mean Serum Albumin (Express Cl! asthe Effect of A Fall o f 10WI)
uud Echocurtliogruphic and Clin ic al Outcome s III The Comb ined Group or Hemodialy sis and
Peritoneal lJillly sil' Patients',
OIJTCOM E
Degreeo f":
Conccnu-ie LV hypcrtrophy"(glll )
I.Vl lilaltl liolld(m l/m1)
Systolic d yslilllction' WuFS)
1'1\."SCI1CC u f:
NlIfl1l:11 ( reference CalCtlllry)




h ( p )
NA









Denovo 1.1'2 (OJ lll7)
Re current I .HO (CH )) )
Isch emicheart disease :
De noco ~ .1 2 (o.m?)
Rec urrent NA
Death:
C a rdiac 2 .54 « OJKI1)
Non-cardiac 2.13 « OJKII )
a. LVI Idenote s Icllvcmnculurhypcn rophy. NAno suuisticul nssocinnon. FS 1"r;lctillu,11s hollcning.
OR od dsmtio nnd RR relative r isk
b. A djusted f o r age. dia betes. ischemic h e-mdise use (cxc judcd fo r ibc «mcomcs de nll l'll un d
recurrent ischemic hc a n disease) andthe average monlhly mean urtcrlnl blood press ure . seru m
albu minund hemoglobin level b e lill'lllhc indexeve n t.
c. ln the group withcir hc rnnrrna l LVor co ncentric L VII.
dln thegroup withcl t bc rnormul Lvur LV dil,llutio n
c. In thegroup witheit he r norm a l LVor systnllc dys function.
Iuhle J I. Assncia litll1Betwe en Mean Serum Albumin Level (Expressed as the Effect of A Fall of
III gil) ;URI Echocurdiugmphic lind Ciin iclli Outcomes Analyze d Separately in Hemod ialysis end
I'crilunC(l1Dialysis I'alicnls· ,
(lt JTC '( )MI ~ I IEMO DlAL YSIS
AdjustcJ hb(p)
Concentric I.VI I' (gllll~ ) NA
Systolic dysfunction" (0/" I'S ) NA
Adj uSlcJhOR
I'rcsc llcc uf :

















Tabl e Jt .voutlnucd.
OUTCOME I [E~'I(}J)lAI.YS IS 1· l m.rl'(lN I ~t\I .I )It\ I.Y:-iI:-i
Adjus tcd h RR A\t! llstc\lhR I{
Cardiac failure :
De novo 2. 22 (0.001) 4. 16 ((W (l) )
Recurrent 3.M (0.003) NA
lschc michcart discnsc:
Denove S.29 (O.OOI) N/\
Recurrent 4 .24 (O.OOS) NA
Dcatlu 4. 33 ceunnn 2.0(, I- ll .On])
Cardiac S.60 (O.()(Jl) NA
Non-cnrdinc 3.SK «O.(J()]) 352 ( - 0.(01)
a. li D denotes hemodialys is. PO peritoneal dialysis, LVI I lcll vent ricu lnr hype rtrophy , NA llll
statistical association. rs fractional shorte ning, OR od ds ratio and l{[{ relat ive risk.
b. A dj usted lo r age. diabetes. ischem ic heart diseuse [excluded fo r the outc omes de Table ) I .
conti nued.novo r md recurrent isc he mic heart disease) and the uvcmgc monthly mcnn ,lrle r;H] hhHlU
press ure. serum album in and he moglobin level before the index event.
e. ln the group w ith either uormn t I.V or concentric I.VII .
d. ln the group w ith e ither norma l Lv or LV d ilatat io n
e. In the gro up w ith eit he r nonnal LV or sys tolic dys function .
Table 32. Assuci,llion Between Mean Serum Calcium . Ino rga nic Pho sphorus a nd
i\l kuline Phuspluuusc Levels and Mortality .
Adjustedh R [{ (1')
A1.1. I'ATIENTS :
Scnnn culcinm ~2.211l111nl/l
Phosphorus > l .t) mlllu lll
Alkaflnephnspharasc > 120 U/I
I ll iM{)D IAI.YS IS I'A T IEN1'S :
Sl:rllIllCu lcitllll ~2 .2J1l rl1ol/l
Phosphorus > 1.9 111 11101/1
Alk a lincph(,spIUltusl,:> 120 lJI l
PE RIT ONEAL DIA LYSIS PAT IENTS :
Sl,:nlln elllci urn ~.21ll1l1(l1l1
I'h usphorus > 1.9 m mulll










n. Adjusted for uge. diabetes mellit us. ische mic heart disease , smoki ng status und cholestero lleve l
nt baseline, and scrlnl albumin, meun arteria l blood pressure . hemoglobin. calci um , phosphorus an d
alknlinc phnsp hatnsc lcvc]s.
Table 33 . Morb idity : Association Bc\\\'Cen Me;\ll Serum Calcium. lnorgnnic I'htls phnllls nrul
Alkaline Phosphatase Levels And AUlllissi\\l\ lilT De Nov" Ischem ic llcart Diseuse , Recurrent





AI' > 12\l 1\l1l1" 11l
A"jusled~ RR (pl
Ischem ic heart disc uses
Dc uovo 5 .23 «0.000 1) NA NA
Recurrent 2.46 (0.006) NA NA
Curdiuc Iaihnv:
De no vo 2 .64 « 0 .000 1) NA No
RL,\:uITCnt 3 .30 «O.OO O!) NA NA
a. Ca. Pi AI' lind RR denote serum calcium. incrgunic phosphorus. ulkulmc phosphatase nml
relative risk respective ly.
b. Adjusted for age, diabetes mellitus. smoking status nnd chu lesleru l level li t baseline. lUll! scr il1l
a lbumi n . mean arterial bloo d pressure. hemoglobin. calcium . phosphate W IU ulkulinc phuspha1(lSC
levels.
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